Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment.

Clinical features

Pyoderma gangrenosum clinical variants

PG initial description is attributed to Louis Brocq who, in 1908, observed ulcerative lesions characterized by a geometrical and irregular ridge, with an erythematous and infiltrated external slope and undermined internal slope of the lesion border. Brocq termed the disease “phagédenisme géométrique”, highlighting with this definition both the geometrical pattern and the rapidly necrotizing feature of these ulcers [ 1 ].

The current term “pyoderma gangrenosum” was coined by Brunsting and colleagues which described PG classical form as irregular ulcerations with well-demarcated erythematous-violaceus serpiginous borders and atrophic scarring, occasionally associated to infections or inflammatory bowel diseases [ 2 ].

Since these classical descriptions, additional clinical characteristics have been described and the current clinical classification of PG include different variants.

i) Classic ulcerative PG is the most common variant, initially presenting as a tender erythematous inflammatory papule, pustule or vesicle, which eventually starts to expand peripherally and degenerate centrally to produce a painful ulcer. PG ulcer border usually appears violaceous and undermined, while its base is usually necrotic and purulent. In terms of depth, ulcers in classic PG may erode deeply: they generally extend into the subcutaneous tissue and sometimes even further, exposing muscles and tendons. Patients may present with an isolated lesion or with multiple lesions in different phases of development, sometimes coalescing to form larger ulcers. The lower limbs tend to be the most frequently affected site, but lesions may occur in any body area. Finally, lesions in classic PG usually heal by second intention with a characteristic atrophic cribriform scarring (termed Gulliver sign) and a “cigarette paper-like” appearance [ 3 ]. ii) Pustular PG is characterized by the acute onset of discrete pustular lesions with an erythematous halo, mainly involving the trunk and the extensor surfaces. These pustules may then either resolve or progress to form ulcers. Associated fever and arthralgias are frequent. This form is most common amongst patients also suffering from inflammatory bowel disease (IBD) and usually appears during acute exacerbations of the condition [ 4 ]. iii) Bullous PG, also known as atypical PG, represents a superficial form of pyoderma gangrenosum. Patients usually develop painful haemorrhagic vesicles or bullae with blue-gray inflammatory borders, rapidly progressing to superficial ulcers. The most frequently involved site of such lesions are the upper extremities (including dorsal hand) and the face. A significant association between bullous PG and hematological malignancies is recognized – in up to 70% of the reported cases – thus requiring a thorough evaluation for the concomitant presence of hematological disorders [ 3 , 5 ]. iv) Vegetative PG (also known as superficial granulomatous type) unlike other variants, has a gradual onset, slower progression, and only causes mild discomfort. It presents as a non-purulent erosion or superficial ulcer without the classical erythematous to violaceous undermined borders. They most frequently appear on the trunk and often exhibit a verrucous surface [ 3 , 6 ].

PG in uncommon locations

Apart from the four above-mentioned clinical subtypes, two other atypical variants of PG related to surgical procedures and associated to local inflammatory stimuli and pathergy have been recognized:

(i) Post-operative PG, also known as pathergic PG or progressive gangrene of Cullen named from the first surgeon who described it in 1924 represents a rare complication of a wide range of surgical intervention and is characterized by the acute onset of PG-like lesions within surgical sites [ 7 ]. The most common location seems to be the mammary area with a classical sparing of the nipple-areolar complex, although it has been described following a variety of surgeries including cardiothoracic, gynaecological and orthopaedic interventions [ 8 ]. The lesions typically appear after 7 to 11 days after the surgery with painful erythema that rapidly necrotize with small ulcers that could coalesce to form larger ulcerations; wound dehiscence is common. In these cases, differentiating post-operative PG from necrotizing fasciitis is crucial, as wound debridement could worsen a PG-like eruption due to pathergy phenomenon [ 7 ]. Interestingly the majority of the patients (66% in a recent review) do not present an associated comorbidity as compared to classical PG (50% to 75% of associated diseases), and the lesions usually respond to immunosuppressive therapies [ 8 ]. (ii) Peristomal PG occurs in the skin around sites of ileostomy or colostomy as a classical ulcerative PG [ 8 ]. In around 80% of the cases patients have an associated IBD and PG occurs in a variable time – ranging from 1.5 to 23 months - after stoma creation [ 8 , 9 ]. Peristomal PG is more common in women and usually follows an IBD flare, however it could present also in patient with no evidence of IBD [ 9 ]. A prompt diagnosis is crucial for the correct management of this condition and to differentiate it from other stoma-related complications, in order to avoid unnecessary treatments as for the post-operative PG. Local and systemic immunosuppressive treatments are usually effective but, interestingly, stoma replacement and/or closure has been associated with resolution of peristomal PG [ 9 ].

In addition to PG clinical subtypes and localized post-surgical variants, special considerations should be given to paediatric forms and PG involving uncommon anatomical sites (e.g. ano-genital, head-and-neck area and mucosae).

Pediatric PG accounts for approximately 4% of the PG cases and differently from adult-onset PG tends to present with more than one ulceration and a slight predilection for the head-and-neck area, with a higher reported rate of pathergy (around 62% in children compared to 25–30% in adults); in infants and toddler ano-genital involvement was also reported. Pediatric PG equally affects male and female, being idiopathic in half of the reported cases; IBD still represent the most common association (around 20% of the cases) while haematological disorders are less frequently reported compared to adults (8% in children compared to 15–25% in adults) [ 10 ].

Head-and-neck (HN) involvement in PG is rare and usually presents with atypical clinical features: pustular or ulcerating nodules over the face represents a common presentation of this form compared to classical PG; pathergy rates (around 37% of the patients) and recurrence risk (approximately 15%) are higher in this form compared to classical PG. Of note 20% of the patients with HN PG had a previous diagnosis of PG or unspecified ulcers. Ulcerative colitis represents the most common associated diseases in HN PG as opposed to Crohn’s diseases in classical PG. Local tissue destruction and eye involvement is a well-described complication of HN PG, occurring in approximately a third of patients. These features could help clinicians in the differential diagnosis with other ulcerative diseases in the head-and-neck area including granulomatosis with polyangiitis, vasculitis and cancers, although the clinical diagnosis remains challenging [ 11 ].

Mucosal involvement of the oral cavity in PG is extremely rare and could affect the tongue, soft and hard palate, lips, buccal mucosa, gingiva and tonsillar fauces, presenting as painful and sometimes bleeding irregularly shaped ulcers with raised borders; initially a papule or nodule could be observed as in classical PG. Males appear more frequently (65%) affected than women and in 20% of the cases PG cutaneous involvement is not present. An associated systemic disease is detected in the majority of the patients (80%), with Crohn’s disease representing the most common comorbidity. Differential diagnosis of oral PG is broad, especially in the absence of PG cutaneous lesions, as it could mimic several oral ulcerative conditions including infective, inflammatory and neoplastic diseases [ 12 ].

Ano-genital involvement in PG is uncommon, and pose major challenges in differential diagnoses as for the head-and-neck area [ 13 ]; a retrospective study observed a median age of onset of 43 years, with the most affected areas being vulva, penis and perineum; usually, one the three ulcerations were present, exclusively located in the ano-genital area in the majority of the studied patients. Classical ulcerative and post-operative PG were the widely reported clinical variants. IBD and haematological malignancies were associated to ano-genital PG, however in lower rates compared to PG in other anatomical locations [ 13 ]. An interesting review study identified a strong association between vulvo-vaginal PG and rituximab exposure: all the female reported in the study (14 patients) developed PG in the vulvo-vaginal area after rituximab administration at standard doses for different diseases (neoplastic or autoimmune); moreover, rituximab discontinuation led to PG resolution in the majority of the cases (75%) [ 14 ].

Indeed, a minority of PG cases may be drug-induced. Adopting the Naranjo criteria for adverse drug reactions, cocaine/levamisole was identified as a probable cause of PG [ 15 ], although distinguishing true PG from PG-like lesions in levamisole-induced ANCA + vasculitis may be challenging. Other medications possibly linked to PG onset or exacerbations were isotretinoin, propylthiouracil, and the tyrosine-kinase inhibitors sunitinib and gefitinib [ 15 ]. PG may also occur as a paradoxical reaction following IL-17 inhibition [ 16 ], while its appearance after anti- tumour necrosis factor (TNF)-α agents, albeit reported, is still under debate [ 15 , 17 ].

Syndromic forms

In a more restricted subset of patients, PG represents a component of distinct autoinflammatory syndromes [ 18 ], whose prototype is PAPA (pyogenic arthritis, PG and acne), hallmarked by sterile cutaneous inflammation and arthritis and caused by pathogenic variants in PSTPIP1 (proline-serine-threonine phosphatase interacting protein 1) gene that lead to an altered proinflammatory signaling and neutrophil-driven inflammation [ 18 ].

In recent years, the spectrum of autoinflammatory diseases caused by PSTPIP1 mutations or characterized by clinical features similar to those seen in PAPA syndrome has been expanding, encompassing several entities [ 18 , 19 ] as summarized in Table 1 . Table 1 Pyoderma gangrenosum-associated autoinflammatory syndromes Pyoderma gangrenosum, acne, pyogenic arthritis (PAPA) Pyoderma gangrenosum, acne, suppurative hidradenitis ( PASH ) Pyogenic arthritis, pyoderma gangrenosum, acne, suppurative hidradenitis ( PAPASH ) Psoriatic arthritis pyoderma gangrenosum, acne, suppurative hidradenitis ( PsAPASH ) Pustular psoriasis, arthritis, pyoderma gangrenosum, synovitis, acne and suppurative hidradenitis ( PsAPSASH ) Pyoderma gangrenosum, acne, suppurative hidradenitis, ankylosing spondylitis ( PASS ) Pyoderma gangrenosum, acne, ulcerative colitis ( PAC ) Psoriatic arthritis, pyoderma gangrenosum, suppurative hidradenitis, crohn’s disease ( PsAPSC ) Vasculitis, pyoderma gangrenosum, acne, suppurative hidradenitis ( VPASH ) PSTPIP1-associated myeloid-related-proteinemia inflammatory syndrome ( PAMI )

Diagnostic tools and work-up

Although many efforts spent in proposing specific and validated diagnostic criteria, PG remains a diagnosis of exclusion and the integration of clinical, anamnestic and laboratory data is crucial for the final diagnosis. Indeed, no laboratory or histopathological marker exists for this condition.

Table 2 summarizes the three main proposed diagnostic criteria for PG [ 5 , 20 , 21 ]. These three diagnostic criteria (Su and colleagues [ 5 ], Delphi consensus [ 20 ] and PARACELSUS [ 21 ]) have been compared for diagnostic accuracy of PG; PARACELSUS accurately scored 89% of PG patients, followed by Delphi Consensus and Su and colleagues, which each assessed 74% of patients with PG [ 22 ]. Table 2 Overview of proposed diagnostic scoring systems for pyoderma gangrenosum Authors, year, reference Scoring and diagnostic criteria Su et al., 2004 [ 5 ] Both major + ≥ 2 minor criteria = PG • Major: ulcer morphologically consistent with PG; exclusion of other causes. • Minor: pathergy or cribriform scarring; systemic disease associated with PG; histopathologic findings compatible to PG; response to immunosuppression. Delphi Consensus, 2017 [ 20 ] Major criterion + ≥ 4 minor criteria = PG. • Major: biopsy of ulcer edge demonstrating neutrophilic infiltrate • Minor: - exclusion of infection; - pathergy; - history of inflammatory bowel disease or inflammatory arthritis; - history of papule, pustule, or vesicle ulcerating within 4 days of appearing; - peripheral erythema, undermining border, and tenderness at ulceration site; - multiple ulcerations, at least 1 on an anterior lower leg; cribriform or “wrinkled paper” scar(s) at healed ulcer sites; - decreased ulcer size within 1 month of initiating immunosuppressive medication(s). PARACELSUS Score, 2019 [ 21 ] ≥ 10 points = PG likely. Major (4 points): rapid progression; exclusion of other causes. • Minor (2 points): pathergy; associated systemic disease; consistent histopathology; rapid response to therapy. • Additional (1 point): pain; multiple ulcers; cribriform/vegetative scarring; undermined border.

PG differential diagnosis is broad and could be divided in six main categories: (i) infection (bacterial, viral, fungal, protozoal); (ii) systemic vasculitis and vasculopathy, (iii) neutrophilic dermatosis (e.g. Sweet syndrome, subcorneal pustular dermatosis and bullous lupus erythematosus); (iv) vascular; (v) neoplastic and (vi) exogenous tissue injury as reviewed by Weenig and colleagues [ 23 ].

In Table 3 , diagnostic work-up for PG diagnosis wassummarized. Table 3 Diagnostic work-up for pyoderma gangrenosum Step Assessment Clinical Relevance 1. Anamnesis and physical examination Identify rapidly progressive, painful ulcers with undermined violaceous borders. Full body examination is warranted. Inquire into history of recent traumas or surgeries (pathergy phenomenon). Screen for associated systemic diseases (IBD, arthritis, hematologic disorders) and drug history Clinical suspicion is essential. Up to 75% of PG cases have comorbidities. Pathergy positive in up to 30%. 2. Histopathology Elliptical incisional biopsy or a deep punch biopsy, which includes the lesion’s inflamed border and ulcer edge, and penetrates vertically into the subcutaneous tissue. Histology is not pathognomonic but is essential in differential diagnosis. Rule out an infectious disease 3. Laboratory work-up CBC with differential, ESR, CRP, liver and renal function tests, autoimmune panel (ANA, ANCA, RF), serum protein electrophoresis, immunoglobulins. Hypercoagulability studies (e.g. antiphospholipid antibodies). Microbiological swabs/cultures and infectious disease screening. Additional tests according to suspected comorbidity (e.g., calprotectin for IBD). Laboratory findings are non-specific but support differential diagnosis and screen for associated diseases. 4. Exclusion of alternative diagnoses Rule out infection, vasculitis, neoplasia, vascular, and drug-induced ulcers. Correlate clinical, laboratory, microbiological, and histological findings. PG remains a diagnosis of exclusion. 5. Additional assessments (if indicated) Imaging (Doppler US, Chest radiography, MRI/CT for deep involvement/osteomyelitis or neoplasia). EGDS, colonoscopy. Age and symptoms appropriate oncological screening should be considered. 6. Ongoing re-evalutation Reassess diagnosis if lack of response. Monitor for new comorbidities. Consider alternative diagnosis if non-responsive. Diagnosis may evolve over time, especially if initial treatment fails. PG (Pyoderma Gangrenosum), IBD (Inflammatory Bowel Disease), CBC (Complete Blood Count), ESR (Erythrocyte Sedimentation Rate), CRP (C-Reactive Protein), ANA (Antinuclear Antibody), ANCA (Antineutrophil Cytoplasmic Antibody), RF (Rheumatoid Factor), US (Ultrasound), MRI (Magnetic Resonance Imaging), CT (Computed Tomography), EGDS (esophagogastroduodenoscopy)

Histopathology of PG

As mentioned above, PG histopathology is not specific and requires clinical correlation. The major findings in active lesions of the classical ulcerative variant are represented by a tissueneutrophilia with epithelial undermining and ulceration, occasional dermal edema and vascular damage with fibrinoid necrosis, and no evidence of leukocytoclastic vasculitis or bacterial, mycobacterial and fungal infections. Neutrophils are often folliculocentric, and a central unspecific area of suppurative necrosis is often present; an accompanying perivascular and intramural lymphocytic infiltrate with scattered neutrophils is also characteristic [ 3 , 24 ]. With regards to the other clinical variants of PG, bullous subtype presents with an extensive epidermal necrosis with neutrophilic subcorneal, epidermal and/or subepidermal bullae formation joint with a dense dermal neutrophilic infiltrate [ 3 , 24 ]. Vegetative PG presents with pseudoepitheliomatous epidermal hyperplasia and a dermal palisading granulomatous reaction with neutrophilic abscesses and sinus tracts [ 3 , 24 ]. Pustular PG variantsare characterized by a subcorneal neutrophil accumulation and/or a follicular and perifollicular neutrophil accumulation with suppurative features [ 3 , 24 ]. PG cases associated with Crohn’s disease may exhibit granulomatous features [ 24 ].

The appropriate clinical setting and clinical correlation could differentiate PG lesions from its histopathological mimicker, i.e., Sweet syndrome (which is rarely folliculocentric), a severe vesicular-necrotic insect bite reaction, a pustular drug reaction, and neutrophilic folliculitis in the setting of rheumatic diseases [ 24 ]. As stated above, an appropriate biopsy should be performed on the active ulcer edge and reach the deep dermis and subcutaneous tissue; the timing of biopsy is also fundamental, as very incipient lesions or older/resolving ulcers may show non-specific histopathological findings [ 24 ].

Making the diagnosis in such instances represents a challenge of utmost therapeutic importance, as reliance on biopsy results should limit or delay treatment initiation. Rather, a practical, ex-adjuvantibus approach may be encouraged, especially if infectious causes have been excluded.

Scoring systems and patient reported outcomes

Given the rarity of PG, there are no currently validated or widely available outcome measures, both clinical and patient reported, for this disease. This lack in validated measurement could affect patient’s management in clinical practice and clinical trials interpretability leading to limitations in newly therapeutic development and evidence-based treatment [ 25 ].

Though a specific quality of life (QoL) questionnaire for PG is not available, the psychological and social burden of the patient is high, as demonstrated by the high scores in Dermatology Life Quality Index (DLQI) and the frequent association with depression [3]. The impact on quality of life is multifaceted, and an interview analysis identified 8 domains which were critically affected and differentiated by PG patients: pain, physical limitations, hygiene, self-image, mental health, sexual intimacy, wound care and disease course [ 26 ]. Among all the domains pain seems to be the most important factor in deteriorating QoL, and improvements in pain numerical rating scale (NRS) could correlate with the physician global assessment (PGA) score [ 3 , 27 ].

Recently an effort to provide a core set domain for PG to be used in interventional clinical trials was promoted on behalf of the UPGRADE initiative, which through a rigorous process involving experts, patients, researcher and industries identified three main domains to be included in the core set: (i) pain, (ii) quality of life and (iii) clinical sign [ 25 ].

Validated PG-specific instruments to measure these domains will be the next step of the consensuswork [ 28 ].

In the meanwhile, the 5-point Global Pyoderma Gangrenosum (GPG) Severity Score has been proposed for the upcoming phase III trial on the Interleukin (IL)−36 receptor inhibitor spesolimab ( NCT06092216 ) [ 29 ].

Epidemiology

The exact epidemiology of PG remains difficult to estimate since only a few population-based studies have been conducted so far. In addition, the difficulty in correctly diagnosing PG might impair the accuracy of estimates.

One of the first studies conducted in UK showed an incidence rate of about 6 per million person-years with a median age at PG presentation of 59 years and no gender predominance [ 30 ]. The largest cross-sectional study from the USA recently reported a worldwide incidence of PG estimated at 3–10 cases per million people with a prevalence of about 58 per million adults-years. Patients over 50 years of age accounted for nearly 70% of all PG cases with a female-to-male ratio of >1.8 [ 31 , 32 ]. Associated diseases have been found in approximately 50 to 75% of PG patients. Epidemiological data are similar across US and different European countries [ 3 ].

It has also been reported that PG patients have a significantly increased mortality rate compared with those of the general population, including a study that found a three folds higher mortality for PG patients compared to age and sex matched controls [ 3 , 30 ].

Etiology

The etiology of PG is multifactorial, encompassing physical trauma, pharmacologic triggers, and coexisting systemic diseases. These factors are thought to interact with dysregulated immune responses, potentially initiating or exacerbating lesion formation; however, the exact pathogenic mechanisms remain incompletely understood [ 30 ].

As mentioned above, a phenomenon commonly associated with PG is the pathergy reaction—a hyperreactive response to minor skin trauma, resulting in new lesions formation at sites of injury. Pathergy manifests in about 30% of PG cases [ 7 ] with even minimal trauma, such as needle punctures, insect bites, or surgical incisions, capable of inducing ulcers in predisposed individuals [ 33 ].

In addition to the previously mentioned role of different pharmacological agents acting as potential triggers [ 15 ], PG may also manifest during pregnancy or the postpartum period, phases characterized by elevated neutrophil counts and systemic inflammation, which could exacerbate PG in susceptible individuals [ 34 ].

A significant etiological component of PG is its frequent association with systemic diseases, reported in up to 50% of cases. The most common associations are with IBD, arthritis, and hematologic disorders [ 35 ]. Clinical observations often indicate that these systemic diseases precede the onset of PG. Specifically, IBD is present in 15–30% of patients with PG, whereas PG develops in approximately 0.5–2% of individuals diagnosed with IBD [ 36 ]. PG activity may coincide with IBD flares but can also arise independently. Notably, the improvement of one condition occasionally corresponds with improvement in the other.

Arthritis is observed in approximately 10–20% of PG cases, most frequently presenting as rheumatoid arthritis or seronegative spondyloarthropathies, including ankylosing spondylitis and psoriatic arthritis. PG has additionally been associated with peripheral arthritis and various inflammatory joint diseases of unclear etiology [ 37 ].

Hematologic disorders associated with PG, present in 7–15% of cases, include monoclonal gammopathies—primarily IgA gammopathy—and hematologic malignancies such as acute myeloid leukemia and myelodysplastic syndromes. In PG patients, monoclonal gammopathies may progress to multiple myeloma; however, current evidence does not indicate a significantly higher progression rate than in cases without PG [ 38 ].

Importantly, monoclonal gammopathy of undetermined significance (MGUS) associated with PG should be thought of as a monoclonal gammopathy of cutaneous significance and, following careful discussion of the possible risks with the patient, may be treated actively.

PG has also been linked to other neutrophilic dermatoses and autoimmune conditions, such as subcorneal pustular dermatosis, Behçet’s disease, Sweet’s syndrome, and systemic lupus erythematosus (SLE) [ 39 ]. In addition to the well-established associations of PG with specific systemic diseases, multiple reviews have identified potential links with other conditions. The clinical relevance of these associations varies, and some are considered anecdotal due to limited evidence of a direct correlation. Among these, diabetes mellitus can complicate management of PG by impairing wound healing, increasing infection risk, and potentially exacerbating inflammation. The prevalence of diabetes among PG patients varies, with some studies indicating that up to 15% of patients may have concomitant diabetes [ 40 ].

Pathogenesis

Available evidence on the pathophysiology of PG points towards a close interaction between neutrophil dysfunction, overexpressed inflammatory mediators and dysregulated components of both innate and adaptive immune response upon a predisposing genetic background, in which the follicular unit has been proposed as the initial target of subclinical inflammation [ 41 ].

Consistent with its classification within the spectrum of neutrophilic dermatoses (NDs), a wide range of data confirmed the role of neutrophils in PG pathogenesis. Indeed, tissue array analyses identified different overexpressed pro-neutrophils markers, including IL-8, chemokine (C-X-C motif) ligand (CXCL) 1/2/3/16 and RANTES (regulated on activation, normal T-cell-expressed and secreted) in PG lesional skin [ 42 ]. In PG, IL-8, also known as CXCL8, is secreted by several cell types such as dermal fibroblasts, endothelial cells, T lymphocytes and macrophages and acts as one of the major mediators of the inflammatory response functioning as a potent chemoattractant for neutrophils and angiogenic factor [ 42 ]. Similarly, TNF-α is a central pro-inflammatory cytokine and has been found to be overexpressed in both PG lesional tissue and serum [ 42 ]. Extensive crosstalk between these two inflammatory networks might favour a persistent neutrophil function and recruitment in PG tissue; furthermore, the release of IL-8 and TNF-α seems to be potentiated by CD40/CD40L and Fas/FasL system, both belonging to the TNF/TNF receptor superfamily and found to be increased in lesional PG [ 42 ]. Some evidence also reported a role of G-CSF (granulocyte colony-stimulating factor), a pleiotropic cytokine with specific effects on the proliferation, differentiation and activation of hematopoietic cells of the neutrophilic granulocyte lineage, in PG pathogenesis [ 43 ], although further mechanistic studies should be required.

Neutrophil activity is tightly regulated by three main strategies, (i) phagocytosis, (ii) degranulation and (iii) release of neutrophil extracellular traps (NETs). This latter are structures composed of DNA-histone complexes and anti-microbial proteins able to entrap bacteria, fungi, protozoa and virus as well as stimulate the release of proinflammatory mediators and cause vascular endothelium damage [ 44 ]. An enhanced formation of NETs has been reported in several immune-mediated inflammatory diseases, including PG and its syndromic form PAPA [ 45 ]. Interestingly, some evidence has also emphasized the presence of NETs with an enrichment of low-density granulocytes (LDGs) signature in PAPA lesional skin [ 45 ]. LDGs are a proinflammatory subset of neutrophils that express cell-surface markers of both terminally differentiated and immature neutrophils and are considered highly proinflammatory because of the increased spontaneous NETs formation and cytokine release [ 45 ]. Although there is no evidence yet, it is plausible that NETs/LDGs may contribute to the pathogenesis of sporadic PG, as previously demonstrated for other immune-mediated inflammatory conditions. Further confirmation of the pathogenic role of neutrophils comes from some recent molecular studies [ 46 – 48 ], in which signaling pathways linked to neutrophil-related inflammation and neutrophil homeostasis/activation/degranulation appeared to be nodal pathogenic drivers in PG pathogenesis. One of these studies [ 46 ] also revealed, in terms of differentially expressed genes (DEGs), an involvement of complement cascade within the perilesional dermis of PG patients. The complement-activated product, C5a, is a strong chemoattractant for different immune cells, including neutrophils, which in turn promote its function through a self-amplification process. Growing data suggest that C5a is a crucial bridge between innate and adaptive immunity, thus extending its role in inflammation; in PG, its blockage might ameliorate neutrophilic inflammation and promote ulcer healing.

In the pathogenic scenario of PG, one of the more interesting aspects lies in the recent evidence supporting that follicular adnexal structures may be the initial target [ 41 , 49 ]. Following inflammatory priming in genetically predisposed individuals, perivascular and peripilosebaceous T-cells skew towards a T helper (Th)1/Th17 phenotype. Alongside Th17 activation and multiple interactions between the follicular/interfollicular epithelium and immune cells, a complex neutrophil-dominant autoinflammatory mileu, with elevated levels of TNF-α, IL-1 α/β, IL-8, IL-12, IL-15, IL-17, IL-22, IL-23 and IL-36 occurs. It has also been proposed that once that Th17 response is well-established, local Th9 cells mediate the release of IL-9, which in turn is downregulated by interferon (IFN)-γ through dendritic cells modulation of IL-27 [ 50 ].

Although the immune-inflammatory signature shows neutrophils as the principal actors during active ulcerative stage, a role of fibroblasts, monocytes/macrophages, natural killer (NK) and B-cells has also been assumed [ 51 ], although additional research is needed.

Th2 related molecules including IL-4, IL-5, IL-13 and C-C motif chemokine receptor (CCR) 3 have been found to be overexpressed in PG tissue compared with healthy controls (HCs). Since IL-4 and IL-5 are important mediators in B lymphocyte proliferation and differentiation, this may be indicative of B-cell involvement in PG pathogenesis [ 51 ]. At the same time, the marked reduction of Th2-mediators compared with the predominant Th1‐signature may underlie the aggressive course of the disease as well as refractoriness of PG lesions in the absence of immunosuppressive agents [ 52 ]. Furthermore, as previously described, the pathogenic role of NETs has been proved in different autoinflammatory diseases including, among others, hidradenitis suppurativa (HS). In the latter, Byrd et al., [ 53 ] in addition to an increased frequency of CD86 + B cells, plasma cells and IgG, found elevated autoantibodies reactive to different citrullinated proteins in NETs, thus hypothesizing that enhanced autoantigens generation, through increased NET formation, could play a role in promoting a dysregulated adaptive immune response. It has therefore been speculated that a similar mechanism may also occur in PG, although evidence is currently scarce [ 51 ].

The contributory role ofadaptive immunity was previously demonstrated by the presence of CD3 + T lymphocytes in the inflammatory infiltrate of PG’s wound edge [ 42 ] and T cell oligoclonality in response to some form of autoantigens [ 54 ]. Moreover, a reduction of regulatory T cells (Tregs) supported the hypothesis of a dysregulated T cell response, thus allowing an uncontrolled activation of effector T cells, such as Th17 cells [ 55 ].

It has been also demonstrated that activation of monocyte/macrophage cell lineage is able to produce IL-15, a key cytokine involved in wound repair and regeneration and found to be overexpressed in PG dermal perivascular regions [ 52 ]. IL-15 is a pleiotropic cytokine that plays an important role both in innate and adaptive immunity, protecting neutrophils from apoptosis, stimulating IL-8, TNF-a, IL-6 and IL-1 secretion and promoting lymphocyte and NK cell proliferation and function. As for IL-15, an increased expression of NK cell marker CD56 has been found in PG cell infiltration, suggesting the involvement of IL-15 in NK cell activation and proliferation [ 52 ]. Noteworthy, NK precursors (NKPs) acquire CD122 (IL2Rβ) expression, which is crucial in the signaling transduction of IL-15 via janus kinase (JAK)1/3 and signal transducer and activator of transcription (STAT)5. Therefore, the impairment or loss of one of these components precludes NK cell development, thus highlighting the important role of JAK/STAT pathway in NK cell maturation [ 56 ]. Differential expression of JAK signaling genes, mainly JAK3 and STAT4, has also been reported in a recent molecular study conducted by Ortega et al., finding further confirmation in previous evidence, particularly by that described by therapeutic effectiveness of JAK inhibitors in PG [ 46 ].

IL-15 mRNA is constitutively expressed not only in monocytes/macrophages but also in nonhematopoietic cells such as fibroblasts, whose role has been partially proven in PG pathogenesis [ 41 ]. Indeed, an interesting study demonstrated a significant decrease of CD4 + and CD34 + fibroblasts as well as IL-15 and desmin in PG wound healing compared with active ulcerative stage and unaffected skin. These findings, in addition to suggesting a potential pathogenic role of fibroblasts, revealed the destruction of pilosebaceous unit during PG resolution consistent with the almost complete absence of desmin [ 41 ].

Finally, it’s important to mention the role of genetic variants in this complex scenario. Indeed, in addition to the involvement of the “paradigmatic” gene PSTPIP1 (serine-threonine phosphatase interacting protein 1), pathogenic variants in autoinflammatory genes such as MEFV (mediterranean familial fever), NLRP (NOD-like receptor family pyrin domain containing) 3/12, NOD2 (nucleotide binding oligomerization domain containing 2 genes) and IL1RN (interleukin 1 receptor antagonist), leading to an exacerbated release of IL-1β, have been reported in both syndromic (PAPA, PASH and PAPASH) and sporadic PG [ 18 ]. More recently, other autoinflammatory genes such as NCSTN (nicastrin) and NLRC4 (NLR family CARD domain containing 4) have been identified in PAPASH syndrome whereas causative variants in OTULIN and GJB2 (gap junction protein beta 2), - the latter involved in keratinization pathway -, have been reported in PASH patients [ 57 ]. AIM2 (absent in melanoma 2), a key pathogen sensor capable of initiating the assembly process of inflammasome and leading to the secretion of both bioactive IL-1β and IL-18, appears to play a role in susceptibility to syndromic forms of PG but not to sporadic PG [ 58 ], although validation studies are needed.

Noteworthy, a recent systematic review [ 59 ] with the objective of identifying inborn errors of immunity (IEis) coexisting with PG demonstrated an association between these conditions, reporting additional genetic variants potentially involved in PG pathogenesis. According to the authors, clarify the role of IEIs in the pathogenic context of PG may increase our understanding of the molecular pathomechanisms of this disease.

In conclusion, recent insights into the complex interaction between immune cells and inflammatory signature as well as the role of genetic predisposition has shed light on novel cellular and molecular mechanisms of PG, although further investigation is needed to fully unravel the pathogenesis of this complex disease and build promising therapeutic strategies in the era of personalized medicine.

Pathogenesis-driven treatments

Several immunosuppressants and immunomodulatory agents are currently available for affected patients, in combination with topical pharmacologic therapies, wound management and pain control strategies. However, in recent years, a significant increase of studies has proven the efficacy and safety of biologic therapies and small molecules blockers, which is why the authors are proposing an updated therapeutic algorithm (Fig. 1 ). Fig. 1 Therapeutic algorithm for the management of pyoderma gangrenosum. Created with BioRender.com TNF, Tumour Necrosis Factor; IL, interleukin; C5a, complement component C5a; JAK-STAT, Janus kinase/signal transducer and activator of transcription; R, receptor

Level 1 evidence (Clinical trials data)

Systemic corticosteroids

Corticosteroids (CS) represent an excellent first-line treatment choice for PG worldwide. They exert their immunosuppressive action by affecting transcription factors, thus acting on the regulation of immune-related genes. They promote a reduction of proinflammatory cytokines such as IL-1 and TNF-α, chemokines and cell-adhesion molecules while increasing anti-inflammatory mediators such as IL-10 and T-regs, thus leading to a decreased neutrophil chemotaxis and migration to inflammation sites [ 60 ].

The STOP-GAP (Study of Treatments fOr Pyoderma Gangrenosum Patients) randomised controlled trial showed that prednisolone at a dosage of 0.75 mg/kg/d resulted in clinical remission in up to half of PG cases by 6 months, although about a third of these patients developed recurrence after completing the study [ 61 ]. Patients with milder disease, in the absence of underlying comorbidities, achieved a better clinical response to CS and steroid-sparing agents should be started concomitantly to allow tapering once disease remission is achieved [ 61 ].

The use of CS should be discouraged in patients suffering from obesity, osteoporosis, gastrointestinal ulcers and/or mental illness. Serious adverse events (SAEs) related to CS including acute kidney injury, hyperglycemia, drug-induced diabetes, cellulitis, and bowel perforation have been reported in clinical practice [ 62 ].

Calcineurin inhibitors (cyclosporine and tacrolimus)

Cyclosporine and tacrolimus are calcineurin inhibitors that impairs the transcription of different cytokine genes such as IL-2 and IFN-γ, particularly in activated T cells.

In the STOP-GAP trial, a comparison of prednisolone (0.75 mg/kg/d) and cyclosporine at the dosage of 4 mg/kg/d found no difference in healing rates (47%) of PG lesions by 6 months, inflammation resolution and time to recurrence; in this regard, about 28% of patients treated with cyclosporine and 30% of patients treated with prednisolone had a recurrence after a median of 582 days [ 61 ].

Compared to CS, cyclosporine had fewer SAEs [ 62 ] and it was found to be a more-cost effective treatment option for PG, particularly for lesions of 20 cm2 or greater [ 63 ].

Oral tacrolimus was administered in several patients with satisfactory response, showing a greater potency than cyclosporine. Potential AEs were similar to that of cyclosporine but may be continued longer [ 62 ].

Tumor necrosis factor alpha inhibitors

The overexpression of TNF-α and its related cytokines in PG lesional skin has led to frequent administration of TNF-α antagonists including adalimumab, certolizumab pegol, etanercept, infliximab and golimumab for the treatment of PG. Complete remission was observed in 87% of PG patients with disease duration of less than 12 weeks, compared with 69% of those with disease duration of more than 12 weeks [ 62 ].However, higher response rates favour adalimumab and infliximab [ 64 , 65 ]. Indeed, a phase III open-label study conducted by Yamasaki et al., [ 65 ] reported a response rate of 54.5% in subjects receiving adalimumab after 6 months of treatment; similarly, a randomized, double-blind, controlled trial conducted by Brooklyn et al., [ 64 ] demonstrated a clinical benefit in 46% of patients after 2 weeks of infliximab treatment compared to placebo and clinical improvement in 69% of PG patients by week 6.

Certolizumab pegol and golimumab have only anecdotal evidence in PG [ 62 ].

C5a inhibitors

The known role of C5a in neutrophil recruitment, wound healing, and complement dysfunction seen in PG lesional skin make it a promising therapeutic target for PG [ 46 ].

Vilobelimab is a first-in-class chimeric monoclonal antibody (mAb) that highly and effectively inhibits activity of complement factor C5a while leaving the formation of the membrane attack complex (C5b-9) intact as a defence mechanism of the innate immune system. A phase IIa open-label study testing the efficacy and safety of vilobelimab (IFX-1) ( NCT03971643 ) [ 66 ] showed that 85.7% of PG patients achieved clinical remission with closure of the target ulcer as assessed by Physician’s General Assessment (PGA) score (equal to or less than 1.15). A phase III clinical study is currently underway to investigate its efficacy and safety in the treatment of PG [ 66 ].

Although no other trials with complement inhibitors are currently under investigation for PG, potential alternatives including (i) avacopan (formerly CCX168), an allosteric C5a receptor (C5aR) antagonist approved by Food and Drug Administration (FDA) for anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV); (ii) eculizumab, a humanized mAb that was approved for UC and able to prevent the release of C5a and activation of the terminal complement pathway and (iii) zilucoplan that inhibits C5 cleavage into C5a and C5b, and prevents the C5b-dependent assembly of the MAC (approved for myasthenia gravis) might pave the way for novel therapeutic scenarios for PG management.

Interleukin-1 inhibitors

Consistent with the crucial role of IL-1 in neutrophils activation and inflammasome formation, IL-1 blockers including anakinra, an IL-1 receptor antagonist (IL-1RA) that blocks IL-1α and β, and canakinumab that inhibits the inflammatory activity of IL-1β, have been successfully used for treating PG, including its syndromic manifestations, improving cutaneous and extracutaneous PG lesions [ 18 ].

Canakinumab is the only drug in this class tested in a phase II open label trial [ 67 ], in which 4 out of 5 patients (80%) with steroid-resistant PG showed a decrease in primary ulcer size by week 16. Similarly, another study reported a complete remission of PG in 6 out of 11 patients and clinical improvement in 1 patient [ 68 ].

On the other hand, 10 of 12 patients (83.3%) treated with anakinra experienced either significant clinical improvement or complete resolution [ 68 ].

Interleukin-17 inhibitors

IL-17 inhibitors, including secukinumab (anti-IL-17 A) brodalumab (IL-17RA) and ixekizumab, an anti-IL-17 A/F, have been successfully reported as safe and effective choices for PG [ 69 , 70 ].

A phase II open-label study demonstrated the efficacy of secukinumab in pain reduction in 4 out of 7 patients and significant clinical improvement with decrease of serum inflammatory markers in 2 patients within 32 weeks, although 3 out of these patients worsened [ 71 ].

An ixekizumab phase II study failed to meet its primary endpoint after 12 weeks of treatment ( NCT03137160 ) [ 72 ], although a recent case series documented a complete resolution of PG in all 4 patients after 3 months of treatment.

Although trials on brodalumab are not available, recent evidence reported the complete clinical remission of PG in 3 patients by 12 weeks, one of whom was refractory to secukinumab [ 62 ].

Noteworthy, IL-17 antagonists have also been implicated in inducing PG, most likely due to a paradoxic increase in IL-23 [ 15 , 73 ].

Level 2 evidence (Cohort Studies)

Dapsone

Dapsone is the most common immunomodulatory agent used in PG with anti-inflammatory, anti-bacterial and antibiotic properties. Although its exact mechanism of action is not well understood, it is considered an antineutrophilic agent that exerts its function by inhibiting myeloperoxidase in neutrophils and preventing tissue damage from reactive oxygen species (ROS) [ 32 ].

It is mainly used in combination with other systemic, topical and intralesional CS, antibiotics or TNF-α inhibitors; a retrospective study of 27 patients revealed a 96.9% response rate, of whom 81.3% had partial response and 15.6% achieved complete response after a mean time of 14.3 months. In spite of that, a third of patients developed AEs such as haemolytic anemia and methemoglobinemia in 9.4% and 3.7%, respectively [ 74 ].

Mycophenolate mofetil

Mycophenolate mofetil (MMF) is an immunosuppressive agent and inhibitor of inosine-5’-monophosphate dehydrogenase, a rate-limiting enzyme in de novo synthesis of guanosine nucleotides. Since T- and B-lymphocytes are more dependent on this pathway, MPA acts preferentially in activated T and B lymphocytes by inhibiting their proliferation and suppressing cell-mediated immune responses and antibody formation.

It has been evaluated as a first-line or second-line steroid-sparing agent and used concomitantly with systemic CS in patients with PG [ 75 ]. In this retrospective study of 26 patients treated with MMF and prednisolone, 84.6% showed clinical improvement, of whom 50% achieved complete healing within an average time of 12.1 months. Unfortunately, 5.8% of patients experienced side effects, although most of them were mild (26.9%) [ 76 ].

The safety and efficacy of MMF has also been documented in the clinical setting of refractory PG or in patients who declined biologic treatments [ 69 ].

Overall, the use of MMF allowed patients to reduce their mean doses of systemic CS, appearing an efficacious and well-tolerated adjunctive therapy option for PG [ 62 ].

Topical corticosteroids and intralesional corticosteroids

High-potency topical CS have been found to be effective mainly for the treatment of mild or localized PG. The most widely used is clobetasol propionate; in a prospective cohort study of 66 patients under treatment with clobetasol propionate 0.05% cream monotherapy, 43.8% of these patients healed by 6 months. Similarly, the use of intra-lesional steroid injections is widely recognized, often for the treatment of peristomal PG because it is administered intermittently when changing ostomy appliances and does not interfere with device adhesion [ 77 ].

Overall, caution is recommended with higher concentrations or injection volumes as skin atrophy is a common side effect.

Topical calcineurin inhibitors

Topical calcineurin inhibitors include tacrolimus, pimecrolimus, and cyclosporine that inhibit T-cells activation and proliferation and the secretion of various pro-inflammatory cytokines.

Topical tacrolimus ointment 0.1% resulted in complete ulcer healing in 50% to 100% of PG patients within 2 to 6 months, thus representing an effective first-line treatment for mild PG. It’s important to mention that renal injury was recorded after applying topical tacrolimus on open wounds [ 77 ].

In contrast, topical pimecrolimus, having less systemic absorption than topical tacrolimus, might be a safer choice for mild PG or as adjuvant therapy in moderate-to severe form of PG [ 62 ].

Similarly, topical cyclosporine, which has shown a remarkable response rate, could represent a promising option as it appears to be free of the tolerability problems associated with systemic administration [ 62 ].

Of note, topical calcineurin inhibitors are also recommended for an adequate control of wound bed and perilesional inflammation in the setting of wound care during the inflammatory phase [ 78 ].

Level 3 (Case-Control Studies) and Level 4 (Case Series or Case Reports) Evidence

Table 4 [ 79 – 114 ] summarized the multiple treatments, in terms of conventional systemic and topical therapies, biologic agents and small molecules, supported by level 3 and 4 evidence, that have proven effective for the treatment of PG.

Table 4 Multiple treatments, supported by level 3 and 4 evidence, that have proven effective for the treatment of pyoderma gangrenosum Drug Mechanism of action Current level of evidence Clinical outcome Conventional systemic and topical therapies Intravenous immunoglobulin i) Neutralizes pathogenic circulating antibodies; ii) inhibits antibody production, complement activation and migration of inflammatory cells; iii) induces autoreactive T cells apoptosis 3 1) In addition to immunosuppressive therapy, 44 out of 50 patients (88%) had response rate; 53% of these PG patients achieved complete healing within 6 months without SAEs [ 79 ] 2) Of 45 PG patients refractory to different treatments, 51% of those healed completely [ 80 ] Methotrexate i) Inhibits cells division; ii) increases lincrNa-p21 expression, which regulates immune responses 4 1) Successfully used as a steroid-sparing agent in association with different conventional systemic therapies or anti-TNFα [ 18 , 81 ] 2) Intralesional MTX was also used as an adjuvant therapy to oral CS allowing patient to achieve almost complete ulcer healing by 7 weeks of therapy [ 82 ] Azathioprine Affects lymphocyte activation and antibody production 4 Successfully used as a steroid-sparing agent in combination with other conventional systemic and topical therapies as well as infliximab [ 83 ] Colchicine Prevents the activation, degranulation, and migration of neutrophils 4 Used as maintenance monotherapy [ 84 ] Thalidomide Modulates NF-κB-related proinflammatory cytokines and chemokine 4 1) It has been proposed as monotherapy or in combination with CS or dapsone [ 85 ] 2) Successfully used in paediatric PG population [ 86 ]. Topical timolol Acts as a nonselective β-adrenoblocker 4 It has proven effective as an adjunct for localized/persistent PG, especially in non-inflammatory phase [ 87 ] Topical phenytoin Promotes fibroblast proliferation, collagen deposition, and neovascularization, while also reducing inflammation, edema, and bacterial load 4 6 patients showed a clinical improvement of PG lesions, although 5 were concomitantly treating with systemic therapy [ 88 ] Granulocyte and monocyte adsorption apheresis Extracorporeal treatment capable of removing activated myeloid lineage leukocytes, with the great potential to decrease inflammation and tissue damage 4 Successfully used, either as in monotherapy or in combination with systemic CS and biologics, in several cases of PG, including two PASH patients [ 62 , 69 , 89 ] Biologic agents Ustekinumab Selectively targets p40 subunit of IL-12 and IL-23 3 1) Of 34 PG patients, 79% experienced clinical improvement whereas 71% healed completely [ 90 ] 2) A case-control study of 28 patients reported a response rate of 68% for all clinical variants of PG [ 91 ] Tocilizumab Inhibits IL-6, which i) exerts stimulatory effects on T-and B cells; ii) activates intracellular signaling cascades through JAK1/STAT3 pathway; iii) favours a Th17-skewed inflammation; iv) participates in neutrophil activation and accumulation in inflammation site 4 1) Successfully used in a single patient with PG and concomitant RA [ 92 ] 2) Clinical improvement of PG in a patient diagnosed with Takayasu arteritis [ 93 ], although a paradoxical PG has also been reported after tocilizumab treatment for Takayasu arteritis [ 94 ] i) Tildrakizumab; ii) Guselkumab iii) Risankizumab Target the IL-23 p19 subunit 4 Significant clinical improvement or complete healing after 3 to 8 months of therapy; particular efficacy of guselkumab [ 95 ] and risankizumab [ 96 ] in patients with recalcitrant PG Spesolimab Blocks the receptor of IL-36, preventing the activation of downstream signaling pathways that promote inflammation 4 Successfully used (off-label prescription) in 3 patients with refractory PG: 1) One patient with post-operative PG experienced significant clinical improvement within 5 weeks [ 97 ] 2) In the second patient, a marked improvement of pain and inflammation as well as reduction in ulcer exudation within 48 h of spesolimab infusion occurred; complete healing of PG lesions after several weeks [ 97 ] 3) The third patient showed a complete resolution of all PG ulcers within 3–4 weeks of treatment [ 98 ] Vedolizumab Targets the α4β7 integrin, which specifies the recruitment of T cells 4 Five patients with IBD experienced an improvement of PG (in combination with both conventional systemic therapies [ 99 , 100 ] and biologics/small molecules [ 101 , 102 ] Of note, vedolizumab-induced PG has also been reported in IBD patients [ 103 ] Visilizumab Binds to the CD3 receptor on certain activated CD8 + and CD4 + naive T cells 4 A patient with PG and UC achieved complete healing after 6 months of therapy (5 mcg/kg/dose intravenously) [ 104 ] Rituximab Targets CD20 (expressed at most stages of B-cell development 4 It has proven safe and effective for the treatment of both PG-like ulcers in association with granulomatosis with polyangiitis [ 105 ] and refractory PG ulcers in the absence of associated conditions [ 106 ] Of note, it has been reported that it may be implicated in most cases of new-onset PG during biologic therapies [ 14 ] Bortezomib Inhibit the proteasome 4 Prompt healing in PG cases with concurrent hematologic diseases, such as IgA gammopathy of undetermined significance [ 107 ,108] and smoldering multiple myeloma [ 109 ] Ixazomib Inhibit the proteasome 4 Complete remission in just a few weeks since initiation of therapy in a case of PG with concurrent IgA smoldering multiple myeloma [ 110 ] Small molecules Tofacitinib Inhibits JAK1 and JAK3 4 Of 17 PG patients, 10 achieved complete resolution within a median of 12 weeks [ 111 ] i) Ruxolitinib; ii) Baricitinib Inhibit JAK1 and JAK2 4 1) Ruxolitinib ( n = 2) appeared safe and effective in the treatment of PG associated with polycythemia vera [ 111 ] 2) Baricitinib ( n = 5) has shown PG ulcer healing when used to treat underlying comorbidities [ 110 ] Upadacitinib Selectively targets JAK1 4 Complete remission ( n = 4) with a median of 12 weeks [ 112 ] Apremilast Inhibits PDE-4, responsible for hydrolysing cAMP, which promotes the downstream expression of numerous pr-inflammatory cytokines and downregulates anti-inflammatory cytokines such as IL-10. 4 1) In one patient with 3-year history of recalcitrant vegetative PG, apremilast was added to systemic CS and MTX and complete healing was achieved at 4 months [ 113 ]. 2) One patient with 5-year history PG in the absence of comorbidities experienced clinical improvement by 4 months and complete remission after 3 years of therapy [ 114 ] 3) One PG patient with concomitant colonic CD showed a marked reduction of PG skin lesions after 19 weeks of therapy [ 101 ] SAE serious adverse events, lincrNa p53-induced long noncoding RNA, MTX methotrexate, CS systemic corticosteroids, NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells, IL interleukin, RA rheumatoid arthritis, IBD inflammatory bowel disease, UC ulcerative colitis, JAK Janus kinases, STAT signal transducer and activator of transcription proteins, PD3E-4 phosphodiesterase-4, cAMP cyclic adenosine monophosphate

Different biologics, small molecules and advanced therapies are also currently under investigation for the treatment of PG (Table 5 ) [ 29 , 66 , 120 ). Table 5 Biologics, small molecules and advanced therapies currently under investigation for the treatment of pyoderma gangrenosum registered at ClinicalTrials.gov database Therapeutic Agent NCT identifier Mechanism of action Current phase of development Notes (e.g., signals of effectiveness/safety) Approved/commercially available (e.g., for other indications) Reference Vilobelimab NCT03971643 mAb that blocks complement factor C5a 3 Phase 2a study ( NCT03971643 ) demonstrated treatment response rates correlated with suppression of C5a levels in patients’ plasma over time. COVID-19 66 Guselkumab NCT06563323 mAb that blocks IL-23 2 Effectiveness has been reported in some case reports. Plaque psoriasis, psoriatic arthritis, (ulcerative colitis) 115 Baricitinib NCT04901325 Inhibitor of JAK1 and JAK2 2 Effectiveness has been reported in some case reports. Rheumatoid arthritis, atopic dermatitis, alopecia areata, juvenile idiopathic arthritis 116 Deucravacitinib NCT05821374 Inhibitor of TYK2 1 None Plaque psoriasis 117 Autologous Platelet-Rich Plasma NCT05984654 Activate the wound-healing cascade stimulating formation of new blood vessels and collagen in PG ulcers NA Effectiveness has been reported in some case reports. Investigational use in chronic wounds and musculoskeletal conditions. 120 Dehydrated human amnion/chorion membrane NCT05120726 Releases growth factors and anti-inflammatory interleukins, modulates MMP activity, promotes mesenchymal stem cell migration. 4 Effectiveness has been reported in some case reports. Used for managing chronic wounds such as diabetic and venous ulcers. 121 mAb (Monoclonal Antibody), IL (Interleukin), JAK (Janus Kinase), TYK2 (Tyrosine Kinase 2), PG (Pyoderma Gangrenosum), MMP (Matrix Metalloproteinases), NA (Not Applicable) Table 6 Monthly estimated costs and levels of evidence for off-label biologic therapies for pyoderma gangrenosum Biologic Dosage per administration* Dosing frequency* Level of Evidence Monthly cost (UK)** Monthly cost (USA)** Infliximab 5 mg/kg Every 4–8 weeks Level 1 £840-£1,680° $2,480-$4,960° Adalimumab 40 mg Weekly Level 1 £1,408 $14,596 Etanercept 25–50 mg Weekly Level 4 £716 $8,000 Anakinra 100 mg Daily Level 4 £810 $9,330 Canakinumab 150 mg Single dose or more Level 1 £9,928^ $20,484^ Secukinumab 150–300 mg Every 1–4 weeks Level 4 £609-£2,436 $7811-$31,244 Ixekizumab 80 mg Every 4 weeks Level 4 £1,125 $7,292 Brodalumab 210 mg Weekly Level 4 £2,760 $7,340 Ustekinumab 90 mg Every 8–12 weeks Level 3 £716-£1,074 $4,889-$7,335 Guselkumab 100 mg Every 4–8 weeks Level 4 £2,250-£4,500 $14,617-$29,345 Risankizumab 150 mg Every 8–12 weeks Level 4 £1,109-£2,218 $7,380 − 14,760 Tildrakizumab 100 mg Every 8–12 weeks Level 4 £1,080 − 2,160 $5,765 − 11,530 Vedolizumab 300 mg Every 8 weeks Level 4 £1,025 $4,567 Tocilizumab 162 mg Every 2 weeks Level 4 £456 $2,770 Spesolimab 900 mg Single dose or more Level 4 £15,000^ $54,929^ *Due to the off-label nature and lack of standardized dosing for PG, the dosage and the frequency for these biologics varies and is often tailored to individual patient needs **Wholesale acquisition costs from manufacturers’ sites, drugs.com, and British National Formulary (last accessed on November 1 st, 2024) °for a patient weighting 80 kg. Cost varies based on patient weight ^Cost per dose

Wound care

Wound care is essential to promote healing. PG-TIME (tissue, infection, moisture balance, and epithelialization) approach has been recently proposed as novel therapeutic algorithm in both the inflammatory and noninflammatory healing phases [ 78 ]. According to this approach, during the inflammatory phase, perilesional skin should be treated with medium-high grade steroids, pimecrolimus, and tacrolimus whereas the wound bed should be treated similarly in both inflammatory and noninflammatory healing phase with appropriate debridement (enzymatic with collagenases or autolytic with hydrogel) and adsorbent dressings such as alginate and hydrofiber. To address critical colonization, antiseptics are recommended. The last phase of epithelialization can be improved with bioactive dressings, allografts, epidermal grafts and skin substitutes [ 78 ]. Although further randomized controlled trials are needed to determine the most effective wound care regimen for the various clinical presentations of PG, several emerging strategies are proving effective, mainly including hyperbaric oxygen therapy, platelet-rich plasma and dehydrated human amnion/chorion membrane allografts.

The role of hyperbaric oxygen (HBO) therapy for wound healing is well known due to its effects on oedema reduction, inflammation control, collagen formation, and bacterial burden mitigation. However, there is very limited evidence documenting the success of treating PG with HBO therapy [ 118 ], and further larger studies are needed.

Platelet-rich plasma (PRP) is a volume of autologous plasma with a platelet concentration above baseline together with endogenous growth factors and cytokines able to promote new vessels and collagen formation. Its efficacy was demonstrated in diabetic foot ulcers and venous leg ulcers for which the probability of complete closure increased 5-fold compared with those treated with conventional treatments. Until now, 2 patients with PG have been successfully treated with 3–4 applications of PRP without any other topical or systemic therapy [ 119 ]. A prospective randomized, split ulcer-controlled trial is currently in progress to assess the efficacy and safety of PRP and whether PRP is more effective as topical solution than as injections [ 120 ].

Finally, dehydrated human amnion/chorion membrane (dHACM) allografts, - skin substitutes containing components of ECM that can be placed in wound beds to accelerate wound healing and decrease pain -, have shown promising results in PG treatment as well. A clinical trial is currently ongoing to evaluate the use of dHACM followed by skin grafting [ 121 ].

Perspectives

Current challenges to be faced in PG care include the need for accurate diagnostic techniques, especially for chronic cases, and effective therapeutics.

While the results of two pivotal trials are expected to provide robust evidence to guide PG management in the future, clinicians should not defer treatment initiation with off-label biologics or their combinations.

Among available treatment options, systemic corticosteroids and TNF-α inhibitors have the greatest body of evidence. In the meanwhile, anti-IL-12/23 and anti-IL-23 agents seem to offer an advantage in terms of safety, tolerability, and efficacy. In the Authors’ opinion, in the future they could be envisioned as backbone therapy, with other agents as addons to address the acute phase.

It is equally important to recognize that adequate treatment of background/associated diseases is instrumental to optimal PG management, both for informing drug choice based on comorbidities and to adequately target its pathogenesis. While this concept has been increasingly incorporated for IBD-associated cases as well as those linked to rheumatological conditions, a paradigm shift for PG related to haematological conditions is still needed. Currently, this is held back by the fear of commencing active treatment for premalignant haematological conditions. However, although certainly there are risks to be carefully discussed with the patients, eradicating the associated haematological neoplasm is sometimes the only way to cure PG and may be best done earlier in the course of the disease, before a decay in the patient status is observed.

In addition to the well-known diagnostic challenges in PG, the lack of standardized disease and patient outcome measures has complicated the monitoring of treatment response, making it difficult to compare the available treatments. The next steps of UPGRADE’s core outcome set (COS) development will involve domain items from existing literature, refining them through e-Delphi surveys until a final consensus is reached [ 28 ]. This project will define more accurate outcome measures in PG clinical trials, thus improving therapeutic strategies and patient care.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author contributions

All authors contributed to the study conception and design. Literature search and data analysis were performed by Chiara Moltrasio, Maurizio Romagnuolo and Carlo Alberto Maronese. The first draft of the manuscript was written by Chiara Moltrasio, Maurizio Romagnuolo and Gianluca Tavoletti. Carlo Alberto Maronese and Angelo Valerio Marzano critically revised the work. All authors read and approved the final manuscript.

Funding

Open access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement. This research was partially supported by Italian Ministry of Health (Ricerca Corrente), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (Italy).

Data availability

All data generated or analysed during this study are included in this published article.

Declarations

Ethics approval

This is a review. No ethical approval is required.

Financial interests

The authors have no competing interests to declare that are relevant to the content of this article.

References

1. Hobbs MM Ortega-Loayza AG Pyoderma gangrenosum: from historical perspectives to emerging investigations Int Wound J 2020 17 5 1255 1265 10.1111/iwj.13389 32378319 PMC7949187 Hobbs MM, Ortega-Loayza AG (2020) Pyoderma gangrenosum: from historical perspectives to emerging investigations. Int Wound J 17(5):1255–1265. 10.1111/iwj.13389 32378319 10.1111/iwj.13389 PMC7949187

2. Brunsting LA Goeckerman W O’Leary P Pyoderma (ecthyma) gangrenosum,clinical and experimental observations in five cases occuring in adults Arch Dermatol 1930 22 655 680 Brunsting LA, Goeckerman W, O’Leary P (1930) Pyoderma (ecthyma) gangrenosum,clinical and experimental observations in five cases occuring in adults. Arch Dermatol 22:655–680

3. Maverakis E Marzano AV Le ST Pyoderma gangrenosum Nat Rev Dis Primers 2020 6 1 81 10.1038/s41572-020-0213-x 33033263 Maverakis E, Marzano AV, Le ST et al (2020) Pyoderma gangrenosum. Nat Rev Dis Primers 6(1):81. 10.1038/s41572-020-0213-x 33033263 10.1038/s41572-020-0213-x

4. Zaino ML Schadt CR Callen JP Pyoderma gangrenosum: diagnostic criteria, subtypes, systemic associations, and workup Dermatol Clin 2024 42 2 157 170 10.1016/j.det.2023.08.003 38423678 Zaino ML, Schadt CR, Callen JP et al (2024) Pyoderma gangrenosum: diagnostic criteria, subtypes, systemic associations, and workup. Dermatol Clin 42(2):157–170. 10.1016/j.det.2023.08.003 38423678 10.1016/j.det.2023.08.003

5. Su WP Davis MD Weenig RH Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria Int J Dermatol 2004 43 11 790 800 10.1111/j.1365-4632.2004.02128.x 15533059 Su WP, Davis MD, Weenig RH et al (2004) Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 43(11):790–800. 10.1111/j.1365-4632.2004.02128.x 15533059 10.1111/j.1365-4632.2004.02128.x

6. Wilson-Jones E Winkelmann RK Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum J Am Acad Dermatol 1988 18 3 511 521 10.1016/s0190-9622(88)70074-2 3351014 Wilson-Jones E, Winkelmann RK (1988) Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum. J Am Acad Dermatol 18(3):511–521. 10.1016/s0190-9622(88)70074-2 3351014 10.1016/s0190-9622(88)70074-2

7. Kipers T Tolkachjov SN Postoperative and peristomal pyoderma gangrenosum: subtypes of pyoderma gangrenosum Dermatol Clin 2024 42 2 171 181 10.1016/j.det.2023.12.001 38423679 Kipers T, Tolkachjov SN (2024) Postoperative and peristomal pyoderma gangrenosum: subtypes of pyoderma gangrenosum. Dermatol Clin 42(2):171–181. 10.1016/j.det.2023.12.001 38423679 10.1016/j.det.2023.12.001

8. Tolkachjov SN Fahy AS Cerci FB Postoperative pyoderma gangrenosum: A clinical review of published cases Mayo Clin Proc 2016 91 9 1267 1279 10.1016/j.mayocp.2016.05.001 27489052 Tolkachjov SN, Fahy AS, Cerci FB et al (2016) Postoperative pyoderma gangrenosum: A clinical review of published cases. Mayo Clin Proc 91(9):1267–1279. 10.1016/j.mayocp.2016.05.001 27489052 10.1016/j.mayocp.2016.05.001

9. Afifi L Sanchez IM Wallace MM Diagnosis and management of peristomal pyoderma gangrenosum: a systematic review J Am Acad Dermatol 2018 78 6 1195 1204e1 10.1016/j.jaad.2017.12.049 29288099 Afifi L, Sanchez IM, Wallace MM et al (2018) Diagnosis and management of peristomal pyoderma gangrenosum: a systematic review. J Am Acad Dermatol 78(6):1195-1204e1. 10.1016/j.jaad.2017.12.049 29288099 10.1016/j.jaad.2017.12.049

10. Moreno-Artero E Torrelo A Pediatric neutrophilic dermatoses Dermatol Clin 2024 42 2 267 283 10.1016/j.det.2023.12.005 38423686 Moreno-Artero E, Torrelo A (2024) Pediatric neutrophilic dermatoses. Dermatol Clin 42(2):267–283. 10.1016/j.det.2023.12.005 38423686 10.1016/j.det.2023.12.005

11. urgdorf AM Gupta AS Latour E Clinical characteristics and misdiagnosis of pyoderma gangrenosum of the head and neck: A retrospective study J Am Acad Dermatol 2022 87 5 1130 1133 10.1016/j.jaad.2022.02.008 35151756 urgdorf AM, Gupta AS, Latour E et al (2022) Clinical characteristics and misdiagnosis of pyoderma gangrenosum of the head and neck: A retrospective study. J Am Acad Dermatol 87(5):1130–1133. 10.1016/j.jaad.2022.02.008 35151756 10.1016/j.jaad.2022.02.008

12. Bissonnette C Kauzman A Mainville GN Oral pyoderma gangrenosum: diagnosis, treatment and challenges: a systematic review Head Neck Pathol 2017 11 4 427 441 10.1007/s12105-017-0804-3 28275955 PMC5677063 Bissonnette C, Kauzman A, Mainville GN (2017) Oral pyoderma gangrenosum: diagnosis, treatment and challenges: a systematic review. Head Neck Pathol 11(4):427–441. 10.1007/s12105-017-0804-3 28275955 10.1007/s12105-017-0804-3 PMC5677063

13. Choe SI Shettig A Kody S Pyoderma gangrenosum of the genitalia, anus, and perineum: two case reports and a review of published cases Sex Transm Dis 2024 51 8 548 550 10.1097/OLQ.0000000000001984 38647256 Choe SI, Shettig A, Kody S et al (2024) Pyoderma gangrenosum of the genitalia, anus, and perineum: two case reports and a review of published cases. Sex Transm Dis 51(8):548–550. 10.1097/OLQ.0000000000001984 38647256 10.1097/OLQ.0000000000001984

14. Croitoru D Nathanielsz N Seigel K Clinical manifestations and treatment outcomes of pyoderma gangrenosum following rituximab exposure: a systematic review J Am Acad Dermatol 2022 87 3 655 656 10.1016/j.jaad.2021.12.028 34942295 Croitoru D, Nathanielsz N, Seigel K et al (2022) Clinical manifestations and treatment outcomes of pyoderma gangrenosum following rituximab exposure: a systematic review. J Am Acad Dermatol 87(3):655–656. 10.1016/j.jaad.2021.12.028 34942295 10.1016/j.jaad.2021.12.028

15. Wang JY French LE Shear NH Drug-induced pyoderma gangrenosum: a review Am J Clin Dermatol 2018 19 1 67 77 10.1007/s40257-017-0308-7 28624960 Wang JY, French LE, Shear NH et al (2018) Drug-induced pyoderma gangrenosum: a review. Am J Clin Dermatol 19(1):67–77. 10.1007/s40257-017-0308-7 28624960 10.1007/s40257-017-0308-7

16. Orita A Hoshina D Hirosaki K Pyoderma gangrenosum caused by Secukinumab successfully treated with risankizumab: a case report and literature review Clin Exp Dermatol 2022 47 7 1372 1374 10.1111/ced.15183 35298047 Orita A, Hoshina D, Hirosaki K (2022) Pyoderma gangrenosum caused by Secukinumab successfully treated with risankizumab: a case report and literature review. Clin Exp Dermatol 47(7):1372–1374. 10.1111/ced.15183 35298047 10.1111/ced.15183

17. Romagnuolo M Moltrasio C Iannone C Pyoderma gangrenosum following anti-TNF therapy in chronic recurrent multifocal osteomyelitis: drug reaction or cutaneous manifestation of the disease? A critical review on the topic with an emblematic case report Front Med (Lausanne) 2023 10 1197273 10.3389/fmed.2023 37324147 PMC10264797 Romagnuolo M, Moltrasio C, Iannone C et al (2023) Pyoderma gangrenosum following anti-TNF therapy in chronic recurrent multifocal osteomyelitis: drug reaction or cutaneous manifestation of the disease? A critical review on the topic with an emblematic case report. Front Med (Lausanne) 10:1197273. 10.3389/fmed.2023 37324147 10.3389/fmed.2023.1197273 PMC10264797

18. Genovese G Moltrasio C Garcovich S PAPA spectrum disorders G Ital Dermatol Venereol 2020 155 5 542 550 10.23736/S0392-0488.20.06629-8 32618443 Genovese G, Moltrasio C, Garcovich S et al (2020) PAPA spectrum disorders. G Ital Dermatol Venereol 155(5):542–550. 10.23736/S0392-0488.20.06629-8 32618443 10.23736/S0392-0488.20.06629-8

19. Maronese CA Moltrasio C Marzano AV Hidradenitis Suppurativa-Related autoinflammatory syndromes: an updated review on the Clinics, Genetics, and treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH), pyogenic Arthritis, pyoderma gangrenosum, acne and suppurative hidradenitis (PAPASH), Synovitis, acne, Pustulosis, hyperostosis and osteitis (SAPHO), and rarer forms Dermatol Clin 2024 42 2 247 265 10.1016/j.det.2023.12.004 38423685 Maronese CA, Moltrasio C, Marzano AV (2024) Hidradenitis Suppurativa-Related autoinflammatory syndromes: an updated review on the Clinics, Genetics, and treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH), pyogenic Arthritis, pyoderma gangrenosum, acne and suppurative hidradenitis (PAPASH), Synovitis, acne, Pustulosis, hyperostosis and osteitis (SAPHO), and rarer forms. Dermatol Clin 42(2):247–265. 10.1016/j.det.2023.12.004 38423685 10.1016/j.det.2023.12.004

20. Maverakis E Ma C Shinkai K Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts JAMA Dermatol 2018 154 4 461 466 10.1001/jamadermatol.2017.5980 29450466 Maverakis E, Ma C, Shinkai K (2018) Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol 154(4):461–466. 10.1001/jamadermatol.2017.5980 29450466 10.1001/jamadermatol.2017.5980

21. Jockenhöfer F Wollina U Salva KA The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum Br J Dermatol 2019 180 3 615 620 10.1111/bjd.16401 29388188 Jockenhöfer F, Wollina U, Salva KA et al (2019) The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol 180(3):615–620. 10.1111/bjd.16401 29388188 10.1111/bjd.16401

22. Haag C Hansen T Hajar T Comparison of three diagnostic frameworks for pyoderma gangrenosum J Invest Dermatol 2021 141 1 59 63 10.1016/j.jid.2020.04.019 32445742 Haag C, Hansen T, Hajar T (2021) Comparison of three diagnostic frameworks for pyoderma gangrenosum. J Invest Dermatol 141(1):59–63. 10.1016/j.jid.2020.04.019 32445742 10.1016/j.jid.2020.04.019

23. Weenig RH Davis MD Dahl PR Skin ulcers misdiagnosed as pyoderma gangrenosum N Engl J Med 2002 347 18 1412 1418 10.1056/NEJMoa013383 12409543 Weenig RH, Davis MD, Dahl PR et al (2002) Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 347(18):1412–1418. 10.1056/NEJMoa013383 12409543 10.1056/NEJMoa013383

24. Crowson AN Mihm MC Jr Magro C Pyoderma gangrenosum: a review J Cutan Pathol 2003 30 2 97 107 10.1034/j.1600-0560.2003.00024.x 12641787 Crowson AN, Mihm MC Jr, Magro C (2003) Pyoderma gangrenosum: a review. J Cutan Pathol 30(2):97–107. 10.1034/j.1600-0560.2003.00024.x 12641787 10.1034/j.1600-0560.2003.00024.x

25. Jacobson ME Rick JW Gerbens LAA UPGRADE. A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative Br J Dermatol 2024 190 3 392 401 10.1093/bjd/ljad420 37952167 Jacobson ME, Rick JW, Gerbens LAA et al (2024) UPGRADE. A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative. Br J Dermatol 190(3):392–401. 10.1093/bjd/ljad420 37952167 10.1093/bjd/ljad420

26. Nusbaum KB Ortega-Loayza AG Kaffenberger BH Health-related domains of quality of life in pyoderma gangrenosum: a qualitative analysis J Am Acad Dermatol 2022 86 6 1382 1385 10.1016/j.jaad.2021.05.040 34058281 Nusbaum KB, Ortega-Loayza AG, Kaffenberger BH (2022) Health-related domains of quality of life in pyoderma gangrenosum: a qualitative analysis. J Am Acad Dermatol 86(6):1382–1385. 10.1016/j.jaad.2021.05.040 34058281 10.1016/j.jaad.2021.05.040

27. Erickson KM Kody S Ortega-Loayza AG Pain as a patient-reported outcome measure in pyoderma gangrenosum JAMA Dermatol 2023 159 11 1274 1275 10.1001/jamadermatol.2023.3115 37728937 PMC10512163 Erickson KM, Kody S, Ortega-Loayza AG (2023) Pain as a patient-reported outcome measure in pyoderma gangrenosum. JAMA Dermatol 159(11):1274–1275. 10.1001/jamadermatol.2023.3115 37728937 10.1001/jamadermatol.2023.3115 PMC10512163

28. Tobey T Ortega-Loayza AG Choe SI Pyoderma gangrenosum refined elements for core item selection and evaluation (PRECISE-PG): a study protocol for reaching consensus on core outcome domain items in clinical trials of pyoderma gangrenosum Arch Dermatol Res 2025 20 1 449 10.1007/s00403-025-03920-w 39979653 Tobey T, Ortega-Loayza AG, Choe SI et al (2025) Pyoderma gangrenosum refined elements for core item selection and evaluation (PRECISE-PG): a study protocol for reaching consensus on core outcome domain items in clinical trials of pyoderma gangrenosum. Arch Dermatol Res 20(1):449. 10.1007/s00403-025-03920-w 10.1007/s00403-025-03920-w 39979653

29. Spesolimab in Pyoderma Gangrenosum https://clinicaltrials.gov/study/NCT06092216?tab=results . Accessed 01.10.2024

30. Langan SM Groves RW Card TR Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study J Invest Dermatol 2012 132 9 2166 2170 10.1038/jid.2012.130 22534879 Langan SM, Groves RW, Card TR et al (2012) Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol 132(9):2166–2170. 10.1038/jid.2012.130 22534879 10.1038/jid.2012.130

31. Xu A Balgobind A Strunk A Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis J Am Acad Dermatol 2020 83 2 425 429 10.1016/j.jaad.2019.08.001 31400451 Xu A, Balgobind A, Strunk A et al (2020) Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis. J Am Acad Dermatol 83(2):425–429. 10.1016/j.jaad.2019.08.001 31400451 10.1016/j.jaad.2019.08.001

32. Orfaly VE Reese AM Friedman M Pyoderma gangrenosum study pilot registry: the first step to a better understanding Wound Repair Regen 2022 30 3 334 337 10.1111/wrr.13005 35363927 Orfaly VE, Reese AM, Friedman M et al (2022) Pyoderma gangrenosum study pilot registry: the first step to a better understanding. Wound Repair Regen 30(3):334–337. 10.1111/wrr.13005 35363927 10.1111/wrr.13005

33. Rashid RM Seat belt pyoderma gangrenosum: minor pressure as a causative factor J Eur Acad Dermatol Venereol 2008 22 10 1273 1274 10.1111/j.1468-3083.2008.02626.x 18837131 Rashid RM (2008) Seat belt pyoderma gangrenosum: minor pressure as a causative factor. J Eur Acad Dermatol Venereol 22(10):1273–1274. 10.1111/j.1468-3083.2008.02626.x 18837131 10.1111/j.1468-3083.2008.02626.x

34. Steele RB Nugent WH Braswell SF Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment Br J Dermatol 2016 174 1 77 87 10.1111/bjd.14230 26474193 Steele RB, Nugent WH, Braswell SF et al (2016) Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment. Br J Dermatol 174(1):77–87. 10.1111/bjd.14230 26474193 10.1111/bjd.14230

35. Kridin K Cohen AD Amber KT Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis Am J Clin Dermatol 2018 19 4 479 487 10.1007/s40257-018-0356-7 29721816 Kridin K, Cohen AD, Amber KT (2018) Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. Am J Clin Dermatol 19(4):479–487. 10.1007/s40257-018-0356-7 29721816 10.1007/s40257-018-0356-7

36. Card TR Langan SM Chu TP Extra-gastrointestinal manifestations of inflammatory bowel disease may be less common than previously reported Dig Dis Sci 2016 61 9 2619 2626 10.1007/s10620-016-4195-1 27193564 Card TR, Langan SM, Chu TP (2016) Extra-gastrointestinal manifestations of inflammatory bowel disease may be less common than previously reported. Dig Dis Sci 61(9):2619–2626. 10.1007/s10620-016-4195-1 27193564 10.1007/s10620-016-4195-1

37. Sawka E Zhou A Latour E Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review Clin Rheumatol 2021 40 10 3963 3969 10.1007/s10067-021-05768-7 34002351 Sawka E, Zhou A, Latour E et al (2021) Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review. Clin Rheumatol 40(10):3963–3969. 10.1007/s10067-021-05768-7 34002351 10.1007/s10067-021-05768-7

38. Maronese CA Derlino F Moltrasio C Neutrophilic and eosinophilic dermatoses associated with hematological malignancy Frontiers in Medicine 2024 10 1324258 10.3389/fmed.2023.1324258 38249974 PMC10796805 Maronese CA, Derlino F, Moltrasio C et al (2024) Neutrophilic and eosinophilic dermatoses associated with hematological malignancy. Frontiers in Medicine 10:1324258. 10.3389/fmed.2023.1324258 38249974 10.3389/fmed.2023.1324258 PMC10796805

39. Delaleu J Lepelletier C Calugareanu A Neutrophilic dermatoses Rev Med Interne 2022 43 12 727 738 10.1016/j.revmed.2022.06.007 35870984 Delaleu J, Lepelletier C, Calugareanu A et al (2022) Neutrophilic dermatoses. Rev Med Interne 43(12):727–738. 10.1016/j.revmed.2022.06.007 35870984 10.1016/j.revmed.2022.06.007

40. Gillard M Anuset D Maillard H Comorbidities of pyoderma gangrenosum: a retrospective multicentric analysis of 126 patients Br J Dermatol 2018 179 1 218 219 10.1111/bjd.16463 29453858 Gillard M, Anuset D, Maillard H et al (2018) Comorbidities of pyoderma gangrenosum: a retrospective multicentric analysis of 126 patients. Br J Dermatol 179(1):218–219. 10.1111/bjd.16463 29453858 10.1111/bjd.16463

41. Wang EA Steel A Luxardi G Classic ulcerative pyoderma gangrenosum is a T cell-mediated disease targeting follicular adnexal structures: a hypothesis based on molecular and clinicopathologic studies Front Immunol 2018 8 1980 10.3389/fimmu.2017.01980 29379508 PMC5775228 Wang EA, Steel A, Luxardi G et al (2018) Classic ulcerative pyoderma gangrenosum is a T cell-mediated disease targeting follicular adnexal structures: a hypothesis based on molecular and clinicopathologic studies. Front Immunol 8:1980. 10.3389/fimmu.2017.01980 29379508 10.3389/fimmu.2017.01980 PMC5775228

42. Marzano AV Fanoni D Antiga E Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and sweet’s syndrome Clin Exp Immunol 2014 178 1 48 56 10.1111/cei.12394 24903614 PMC4360193 Marzano AV, Fanoni D, Antiga E et al (2014) Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and sweet’s syndrome. Clin Exp Immunol 178(1):48–56. 10.1111/cei.12394 24903614 10.1111/cei.12394 PMC4360193

43. Kozono K Nakahara T Kikuchi S Pyoderma gangrenosum with increased levels of serum cytokines J Dermatol 2015 42 12 1186 1188 10.1111/1346-8138.12970 26047254 Kozono K, Nakahara T, Kikuchi S (2015) Pyoderma gangrenosum with increased levels of serum cytokines. J Dermatol 42(12):1186–1188. 10.1111/1346-8138.12970 26047254 10.1111/1346-8138.12970

44. Brinkmann V Neutrophil extracellular traps in the second decade J Innate Immun 2018 10 5–6 414 421 10.1159/000489829 29909412 PMC6784051 Brinkmann V (2018) Neutrophil extracellular traps in the second decade. J Innate Immun 10(5–6):414–421. 10.1159/000489829 29909412 10.1159/000489829 PMC6784051

45. Mistry P Carmona-Rivera C Ombrello AK Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome Ann Rheum Dis 2018 77 12 1825 1833 10.1136/annrheumdis-2018-213746 30131320 PMC6728908 Mistry P, Carmona-Rivera C, Ombrello AK et al (2018) Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome. Ann Rheum Dis 77(12):1825–1833. 10.1136/annrheumdis-2018-213746 30131320 10.1136/annrheumdis-2018-213746 PMC6728908

46. Ortega-Loayza AG Friedman MA Reese AM Molecular and cellular characterization of pyoderma gangrenosum: implications for the use of gene expression J Invest Dermatol 2022 142 4 1217 1220e14 10.1016/j.jid.2021.08.431 34536481 PMC12923208 Ortega-Loayza AG, Friedman MA, Reese AM et al (2022) Molecular and cellular characterization of pyoderma gangrenosum: implications for the use of gene expression. J Invest Dermatol 142(4):1217-1220e14. 10.1016/j.jid.2021.08.431 34536481 10.1016/j.jid.2021.08.431 PMC12923208

47. Moura RR Brandão L Moltrasio C Different molecular pathways are disrupted in pyoderma gangrenosum patients and are associated with the severity of the disease Sci Rep 2023 13 1 4919 10.1038/s41598-023-31914-z 36966241 PMC10039684 Moura RR, Brandão L, Moltrasio C et al (2023) Different molecular pathways are disrupted in pyoderma gangrenosum patients and are associated with the severity of the disease. Sci Rep 13(1):4919. 10.1038/s41598-023-31914-z 36966241 10.1038/s41598-023-31914-z PMC10039684

48. Brandão LAC Moura RR Marzano AV Variant enrichment analysis to explore pathways functionality in complex autoinflammatory skin disorders through whole exome sequencing analysis Int J Mol Sci 2022 23 4 2278 10.3390/ijms23042278 35216413 PMC8877088 Brandão LAC, Moura RR, Marzano AV et al (2022) Variant enrichment analysis to explore pathways functionality in complex autoinflammatory skin disorders through whole exome sequencing analysis. Int J Mol Sci 23(4):2278. 10.3390/ijms23042278 35216413 10.3390/ijms23042278 PMC8877088

49. Moltrasio C, Moura RR, Brandão L et al (2025) Keratin variants in pyoderma gangrenosum: pathogenetic insights from a Whole-Exome Sequencing-Based bioinformatic Analysis. J invest dermatol S0022-202X(25)00115-0. 10.1016/j.jid.2025.01.029 10.1016/j.jid.2025.01.029 39983981

50. Murugaiyan G Beynon V Pires Da Cunha A IFN-γ limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27 J Immunol 2012 189 11 5277 5283 10.4049/jimmunol.1200808 23125412 PMC3504131 Murugaiyan G, Beynon V, Pires Da Cunha A et al (2012) IFN-γ limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J Immunol 189(11):5277–5283. 10.4049/jimmunol.1200808 23125412 10.4049/jimmunol.1200808 PMC3504131

51. Flora A Kozera E Frew JW Pyoderma gangrenosum: a systematic review of the molecular characteristics of disease Exp Dermatol 2022 31 4 498 515 10.1111/exd.14534 35114021 Flora A, Kozera E, Frew JW (2022) Pyoderma gangrenosum: a systematic review of the molecular characteristics of disease. Exp Dermatol 31(4):498–515. 10.1111/exd.14534 35114021 10.1111/exd.14534

52. Antiga E Maglie R Volpi W T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum Clin Exp Immunol 2017 189 3 383 391 10.1111/cei.12989 28518224 PMC5543499 Antiga E, Maglie R, Volpi W et al (2017) T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum. Clin Exp Immunol 189(3):383–391. 10.1111/cei.12989 28518224 10.1111/cei.12989 PMC5543499

53. Byrd AS Carmona-Rivera C O’Neil LJ Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa Sci Transl Med 2019 11 508 eaav5908 10.1126/scitranslmed.aav5908 31484788 PMC11369904 Byrd AS, Carmona-Rivera C, O’Neil LJ et al (2019) Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa. Sci Transl Med 11(508):eaav5908. 10.1126/scitranslmed.aav5908 31484788 10.1126/scitranslmed.aav5908 PMC11369904

54. Brooklyn TN Williams AM Dunnill MG T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking Br J Dermatol 2007 157 5 960 966 10.1111/j.1365-2133.2007.08211.x 17935516 Brooklyn TN, Williams AM, Dunnill MG et al (2007) T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking. Br J Dermatol 157(5):960–966 17935516 10.1111/j.1365-2133.2007.08211.x

55. Caproni M Antiga E Volpi W The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum Br J Dermatol 2015 173 1 275 278 10.1111/bjd.13670 25601218 Caproni M, Antiga E, Volpi W et al (2015) The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Br J Dermatol 173(1):275–278. 10.1111/bjd.13670 25601218 10.1111/bjd.13670

56. Gotthardt D Sexl V STATs in NK-cells: the good, the bad, and the ugly Front Immunol 2017 7 694 10.3389/fimmu.2016.00694 28149296 PMC5241313 Gotthardt D, Sexl V (2017) STATs in NK-cells: the good, the bad, and the ugly. Front Immunol 7:694. 10.3389/fimmu.2016.00694 28149296 10.3389/fimmu.2016.00694 PMC5241313

57. Marzano AV Genovese G Moltrasio C Whole-exome sequencing in 10 unrelated patients with syndromic hidradenitis suppurativa: a preliminary step for a Genotype-Phenotype correlation Dermatology 2022 238 5 860 869 10.1159/000521263 35034021 Marzano AV, Genovese G, Moltrasio C et al (2022) Whole-exome sequencing in 10 unrelated patients with syndromic hidradenitis suppurativa: a preliminary step for a Genotype-Phenotype correlation. Dermatology 238(5):860–869 35034021 10.1159/000521263

58. Moltrasio C Cagliani R Sironi M Autoinflammation in syndromic hidradenitis suppurativa: the role of AIM2 Vaccines 2023 11 1 162 10.3390/vaccines11010162 36680007 PMC9862365 Moltrasio C, Cagliani R, Sironi M et al (2023) Autoinflammation in syndromic hidradenitis suppurativa: the role of AIM2. Vaccines 11(1):162. 10.3390/vaccines11010162 36680007 10.3390/vaccines11010162 PMC9862365

59. Oprea Y Antohi DR Vague M Human inborn errors of immunity in pyoderma gangrenosum: a systematic review Am J Clin Dermatol 2024 25 5 701 716 10.1007/s40257-024-00875-y 38951460 Oprea Y, Antohi DR, Vague M et al (2024) Human inborn errors of immunity in pyoderma gangrenosum: a systematic review. Am J Clin Dermatol 25(5):701–716. 10.1007/s40257-024-00875-y 38951460 10.1007/s40257-024-00875-y

60. Coutinho AE Chapman KE The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights Mol Cell Endocrinol 2011 335 1 2 13 10.1016/j.mce.2010.04.005 20398732 PMC3047790 Coutinho AE, Chapman KE (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335(1):2–13. 10.1016/j.mce.2010.04.005 20398732 10.1016/j.mce.2010.04.005 PMC3047790

61. Ormerod AD Thomas KS Craig FE Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial BMJ 2015 350 h2958 10.1136/bmj.h2958 26071094 PMC4469977 Ormerod AD, Thomas KS, Craig FE et al (2015) Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 350:h2958. 10.1136/bmj.h2958 26071094 10.1136/bmj.h2958 PMC4469977

62. Tan MG Tolkachjov SN Treatment of pyoderma gangrenosum Dermatol Clin 2024 42 2 183 192 10.1016/j.det.2023.12.002 38423680 Tan MG, Tolkachjov SN (2024) Treatment of pyoderma gangrenosum. Dermatol Clin 42(2):183–192. 10.1016/j.det.2023.12.002 38423680 10.1016/j.det.2023.12.002

63. Mason JM Thomas KS Ormerod AD Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial Br J Dermatol 2017 177 6 1527 1536 10.1111/bjd.15561 28391619 PMC5811816 Mason JM, Thomas KS, Ormerod AD et al (2017) Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial. Br J Dermatol 177(6):1527–1536. 10.1111/bjd.15561 28391619 10.1111/bjd.15561 PMC5811816

64. Brooklyn TN Dunnill MG Shetty A Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial Gut 2006 55 4 505 509 10.1136/gut.2005.074815 16188920 PMC1856164 Brooklyn TN, Dunnill MG, Shetty A et al (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55(4):505–509. 10.1136/gut.2005.074815 16188920 10.1136/gut.2005.074815 PMC1856164

65. Yamasaki K Yamanaka K Zhao Y Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: twenty-six-week phase 3 open-label study J Dermatol 2020 47 12 1383 1390 10.1111/1346-8138.15533 32804433 PMC7754463 Yamasaki K, Yamanaka K, Zhao Y (2020) Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: twenty-six-week phase 3 open-label study. J Dermatol 47(12):1383–1390. 10.1111/1346-8138.15533 32804433 10.1111/1346-8138.15533 PMC7754463

66. Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum. https://clinicaltrials.gov/study/NCT03971643 . Accessed 01.10.2024

67. Kolios AG Maul JT Meier B Canakinumab in adults with steroid-refractory pyoderma gangrenosum Br J Dermatol 2015 173 5 1216 1223 10.1111/bjd.14037 26471257 Kolios AG, Maul JT, Meier B et al (2015) Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol 173(5):1216–1223. 10.1111/bjd.14037 26471257 10.1111/bjd.14037

68. McKenzie F Cash D Gupta A Biologic and small-molecule medications in the management of pyoderma gangrenosum J Dermatolog Treat 2019 30 3 264 276 10.1080/09546634.2018.1506083 30051737 McKenzie F, Cash D, Gupta A et al (2019) Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatolog Treat 30(3):264–276. 10.1080/09546634.2018.1506083 30051737 10.1080/09546634.2018.1506083

69. Maronese CA Pimentel MA Li MM Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments Am J Clin Dermatol 2022 23 5 615 634 10.1007/s40257-022-00699-8 35606650 PMC9464730 Maronese CA, Pimentel MA, Li MM et al (2022) Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol 23(5):615–634. 10.1007/s40257-022-00699-8 35606650 10.1007/s40257-022-00699-8 PMC9464730

70. Dissemond J Marzano AV Hampton PJ Pyoderma gangrenosum: treatment options Drugs 2023 83 14 1255 1267 10.1007/s40265-023-01931-3 37610614 PMC10511384 Dissemond J, Marzano AV, Hampton PJ et al (2023) Pyoderma gangrenosum: treatment options. Drugs 83(14):1255–1267. 10.1007/s40265-023-01931-3 37610614 10.1007/s40265-023-01931-3 PMC10511384

71. Lauffer F Seiringer P Böhmer D Safety and efficacy of anti-IL-17 (secukinumab) for the treatment of pyoderma gangrenosum J Investig Dermatol 2021 141 10 156 10.1016/j.jid.2021.08.046 Lauffer F, Seiringer P, Böhmer D et al (2021) Safety and efficacy of anti-IL-17 (secukinumab) for the treatment of pyoderma gangrenosum. J Investig Dermatol 141(10):156. 10.1016/j.jid.2021.08.046

72. An Open-Label Proof-of-Concept study of Ixekizumab in the treatment of pyoderma gangrenosum. https://www.clinicaltrials.gov/study/NCT03137160 . Accessed 01.10.2024

73. Aromolo IF Maronese CA Moltrasio C Genetic findings in a patient with paradoxical pyoderma gangrenosum induced by brodalumab Clin Exp Dermatol 2023 48 3 293 295 10.1093/ced/llac117 36763724 Aromolo IF, Maronese CA, Moltrasio C et al (2023) Genetic findings in a patient with paradoxical pyoderma gangrenosum induced by brodalumab. Clin Exp Dermatol 48(3):293–295. 10.1093/ced/llac117 36763724 10.1093/ced/llac117

74. Din RS Tsiaras WG Li DG Efficacy of systemic Dapsone treatment for pyoderma gangrenosum: A retrospective review J Drugs Dermatol 2018 17 10 1058 1060 30365585 Din RS, Tsiaras WG, Li DG et al (2018) Efficacy of systemic Dapsone treatment for pyoderma gangrenosum: A retrospective review. J Drugs Dermatol 17(10):1058–1060 30365585

75. Li J Kelly R Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent J Am Acad Dermatol 2013 69 4 565 569 10.1016/j.jaad.2013.05.028 23850090 Li J, Kelly R (2013) Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol 69(4):565–569. 10.1016/j.jaad.2013.05.028 23850090 10.1016/j.jaad.2013.05.028

76. Hrin ML Bashyam AM Huang WW Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review Int J Dermatol 2021 60 12 e486 e492 10.1111/ijd.15539 33739458 Hrin ML, Bashyam AM, Huang WW (2021) Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review. Int J Dermatol 60(12):e486–e492. 10.1111/ijd.15539 33739458 10.1111/ijd.15539

77. Thomas KS Ormerod AD Craig FE Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study J Am Acad Dermatol 2016 75 5 940 949 10.1016/j.jaad.2016.06.016 27502313 Thomas KS, Ormerod AD, Craig FE et al (2016) Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study. J Am Acad Dermatol 75(5):940–949. 10.1016/j.jaad.2016.06.016 27502313 10.1016/j.jaad.2016.06.016

78. Janowska A Oranges T Fissi A Pg-time: a practical approach to the clinical management of pyoderma gangrenosum Dermatol Ther 2020 33 3 e13412 10.1111/dth.13412 32291879 Janowska A, Oranges T, Fissi A et al (2020) Pg-time: a practical approach to the clinical management of pyoderma gangrenosum. Dermatol Ther 33(3):e13412. 10.1111/dth.13412 32291879 10.1111/dth.13412

79. Song H Lahood N Mostaghimi A Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series Br J Dermatol 2018 178 2 363 368 10.1111/bjd.15850 28742926 Song H, Lahood N, Mostaghimi A (2018) Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series. Br J Dermatol 178(2):363–368. 10.1111/bjd.15850 28742926 10.1111/bjd.15850

80. Haag CK Ortega-Loayza AG Latour E Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum J Dermatolog Treat 2020 31 7 723 726 10.1080/09546634.2019.1606888 30998080 Haag CK, Ortega-Loayza AG, Latour E et al (2020) Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum. J Dermatolog Treat 31(7):723–726. 10.1080/09546634.2019.1606888 30998080 10.1080/09546634.2019.1606888

81. Wang LL Micheletti RG Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: a retrospective chart review J Am Acad Dermatol 2020 82 2 507 510 10.1016/j.jaad.2019.09.012 31541746 Wang LL, Micheletti RG (2020) Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: a retrospective chart review. J Am Acad Dermatol 82(2):507–510. 10.1016/j.jaad.2019.09.012 31541746 10.1016/j.jaad.2019.09.012

82. Del Puerto C Navarrete-Dechent CP Carrasco-Zuber JE Intralesional methotrexate as an adjuvant treatment for pyoderma gangrenosum: a case report Indian J Dermatol Venereol Leprol 2017 83 2 277 10.4103/0378-6323.186497 27451930 Del Puerto C, Navarrete-Dechent CP, Carrasco-Zuber JE et al (2017) Intralesional methotrexate as an adjuvant treatment for pyoderma gangrenosum: a case report. Indian J Dermatol Venereol Leprol 83(2):277. 10.4103/0378-6323.186497 27451930 10.4103/0378-6323.186497

83. Chatzinasiou F Polymeros D Panagiotou M Generalized pyoderma gangrenosum associated with ulcerative colitis: successful treatment with Infliximab and azathioprine Acta Dermatovenerol Croat 2016 24 1 83 85 27149138 Chatzinasiou F, Polymeros D, Panagiotou M et al (2016) Generalized pyoderma gangrenosum associated with ulcerative colitis: successful treatment with Infliximab and azathioprine. Acta Dermatovenerol Croat 24(1):83–85 27149138

84. Paolini O Hébuterne X Flory P Treatment of pyoderma gangrenosum with colchicine Lancet 1995 345 8956 1057 1058 10.1016/S0140-6736(95)90801-3 7723530 Paolini O, Hébuterne X, Flory P (1995) Treatment of pyoderma gangrenosum with colchicine. Lancet 345(8956):1057–1058 7723530

85. Federman GL Federman DG Recalcitrant pyoderma gangrenosum treated with thalidomide Mayo Clin Proc 2000 75 8 842 844 10.4065/75.8.842 10943240 Federman GL, Federman DG (2000) Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc 75(8):842–844. 10.4065/75.8.842 10943240 10.4065/75.8.842

86. Venencie PY Saurat JH Pyoderma gangrenosum Chez Un enfant. Traitement par La thalidomide [Pyoderma gangrenosum in a child. Treatment with thalidomide (author’s transl)] Ann Pediatr (Paris) 1982 29 1 67 69 7055361 Venencie PY, Saurat JH (1982) Pyoderma gangrenosum Chez Un enfant. Traitement par La thalidomide [Pyoderma gangrenosum in a child. Treatment with thalidomide (author’s transl)]. Ann Pediatr (Paris) 29(1):67–69 French 7055361

87. Moreira C Lopes S Cruz MJ Topical timolol for the treatment of pyoderma gangrenosum BMJ Case Rep 2017 2017 bcr2016218589 10.1136/bcr-2016-218589 28130288 PMC5278339 Moreira C, Lopes S, Cruz MJ et al (2017) Topical timolol for the treatment of pyoderma gangrenosum. BMJ Case Rep 2017:bcr2016218589. 10.1136/bcr-2016-218589 28130288 10.1136/bcr-2016-218589 PMC5278339

88. Fonseka HF Ekanayake SM Dissanayake M 2% topical phenytoin sodium solution in treating pyoderma gangrenosum: a cohort study Int Wound J 2010 7 6 519 523 10.1111/j.1742-481X.2010.00725.x 20722769 PMC7951286 Fonseka HF, Ekanayake SM, Dissanayake M (2010) 2% topical phenytoin sodium solution in treating pyoderma gangrenosum: a cohort study. Int Wound J 7(6):519–523. 10.1111/j.1742-481X.2010.00725.x 20722769 10.1111/j.1742-481X.2010.00725.x PMC7951286

89. Gnesotto L Mioso G Alaibac M Use of granulocyte and monocyte adsorption apheresis in dermatology (Review) Exp Ther Med 2022 24 2 536 10.3892/etm.2022.11463 35837066 PMC9257973 Gnesotto L, Mioso G, Alaibac M (2022) Use of granulocyte and monocyte adsorption apheresis in dermatology (Review). Exp Ther Med 24(2):536. 10.3892/etm.2022.11463 35837066 10.3892/etm.2022.11463 PMC9257973

90. Ben Abdallah H Fogh K Vestergaard C Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review Dermatology 2022 238 4 785 792 10.1159/000519320 34710873 Ben Abdallah H, Fogh K, Vestergaard C et al (2022) Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review. Dermatology 238(4):785–792. 10.1159/000519320 34710873 10.1159/000519320

91. Westerdahl JS Nusbaum KB Chung CG Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes J Dermatolog Treat 2022 33 4 2386 2390 10.1080/09546634.2021.1937475 34057010 Westerdahl JS, Nusbaum KB, Chung CG et al (2022) Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes. J Dermatolog Treat 33(4):2386–2390. 10.1080/09546634.2021.1937475 34057010 10.1080/09546634.2021.1937475

92. Lee WS Choi YJ Yoo WH Use of Tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis J Eur Acad Dermatol Venereol 2017 31 2 e75 e77 10.1111/jdv.13736 27325564 Lee WS, Choi YJ, Yoo WH (2017) Use of Tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. J Eur Acad Dermatol Venereol 31(2):e75–e77. 10.1111/jdv.13736 27325564 10.1111/jdv.13736

93. Choong DJ, Ng JL, Vinciullo C (2021) Pyoderma gangrenosum associated with Takayasu’s arteritis in a young Caucasian woman and response to biologic therapy with tocilizumab. JAAD Case Rep 2021 9(4–6). 10.1016/j.jdcr.2020.12.034 10.1016/j.jdcr.2020.12.034 PMC7868742 33598515

94. Borgia F Sutera D Spagnolo A Onset of pyoderma gangrenosum after Tocilizumab therapy for Takayasu arteritis: a new undescribed paradoxical reaction Br J Clin Pharmacol 2021 87 8 3378 3379 10.1111/bcp.14756 33567476 Borgia F, Sutera D, Spagnolo A et al (2021) Onset of pyoderma gangrenosum after Tocilizumab therapy for Takayasu arteritis: a new undescribed paradoxical reaction. Br J Clin Pharmacol 87(8):3378–3379. 10.1111/bcp.14756 33567476 10.1111/bcp.14756

95. Reese AM Erickson K Reed KB Modified dose of Guselkumab for treatment of pyoderma gangrenosum JAAD Case Reports 2022 21 38 42 10.1016/j.jdcr.2021.11.030 35146098 PMC8818803 Reese AM, Erickson K, Reed KB (2022) Modified dose of Guselkumab for treatment of pyoderma gangrenosum. JAAD Case Reports 21:38–42. 10.1016/j.jdcr.2021.11.030 35146098 10.1016/j.jdcr.2021.11.030 PMC8818803

96. Burgdorf B Schlott S Ivanov IH Successful treatment of a refractory pyoderma gangrenosum with risankizumab Int Wound J 2020 17 4 1086 1088 10.1111/iwj.13359 32266771 PMC7948586 Burgdorf B, Schlott S, Ivanov IH et al (2020) Successful treatment of a refractory pyoderma gangrenosum with risankizumab. Int Wound J 17(4):1086–1088. 10.1111/iwj.13359 32266771 10.1111/iwj.13359 PMC7948586

97. Guénin SH Khattri S Lebwohl MG Spesolimab use in treatment of pyoderma gangrenosum JAAD Case Rep 2023 34 18 22 10.1016/j.jdcr.2023.01.022 36936866 PMC10015112 Guénin SH, Khattri S, Lebwohl MG (2023) Spesolimab use in treatment of pyoderma gangrenosum. JAAD Case Rep 34:18–22. 10.1016/j.jdcr.2023.01.022 36936866 10.1016/j.jdcr.2023.01.022 PMC10015112

98. Ma L Chen X Guo Q Rapid response to Spesolimab in a patient with severe refractory pyoderma gangrenosum Clin Exp Dermatol 2024 49 1 82 84 10.1093/ced/llad317 37706345 Ma L, Chen X, Guo Q (2024) Rapid response to Spesolimab in a patient with severe refractory pyoderma gangrenosum. Clin Exp Dermatol 49(1):82–84. 10.1093/ced/llad317 10.1093/ced/llad317 37706345

99. Fleisher M Marsal J Lee SD Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease Dig Dis Sci 2018 63 4 825 833 10.1007/s10620-018-4971-1 29484571 PMC5854745 Fleisher M, Marsal J, Lee SD et al (2018) Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci 63(4):825–833. 10.1007/s10620-018-4971-1 29484571 10.1007/s10620-018-4971-1 PMC5854745

100. Groudan K Gupta K Singhania R Vedolizumab (Entyvio ® ) for the treatment of pyoderma gangrenosum in a crohn’s disease patient Cureus 2021 13 1 e12582 10.7759/cureus.12582 33457145 PMC7797417 Groudan K, Gupta K, Singhania R (2021) Vedolizumab (Entyvio ® ) for the treatment of pyoderma gangrenosum in a crohn’s disease patient. Cureus 13(1):e12582. 10.7759/cureus.12582 33457145 10.7759/cureus.12582 PMC7797417

101. Vernero M Ribaldone DG Cariti C Dual-targeted therapy with Apremilast and Vedolizumab in pyoderma gangrenosum associated with Crohn’s disease J Dermatol 2020 47 6 e216 e217 10.1111/1346-8138.15283 32347562 Vernero M, Ribaldone DG, Cariti C et al (2020) Dual-targeted therapy with Apremilast and Vedolizumab in pyoderma gangrenosum associated with Crohn’s disease. J Dermatol 47(6):e216–e217. 10.1111/1346-8138.15283 32347562 10.1111/1346-8138.15283

102. Lee HC Kwon Y Kim ES Dual biological therapy for ulcerative colitis with intractable pyoderma gangrenosum Ann Dermatol 2023 35 Suppl 1 S107 S111 10.5021/ad.21.060 37853879 PMC10608359 Lee HC, Kwon Y, Kim ES et al (2023) Dual biological therapy for ulcerative colitis with intractable pyoderma gangrenosum. Ann Dermatol 35(Suppl 1):S107–S111. 10.5021/ad.21.060 37853879 10.5021/ad.21.060 PMC10608359

103. Diaz LI Keihanian T Schwartz I Vedolizumab-Induced de Novo extraintestinal manifestations Gastroenterol Hepatol 2020 16 2 75 81 PMC8132677 34035705 Diaz LI, Keihanian T, Schwartz I et al (2020) Vedolizumab-Induced de Novo extraintestinal manifestations. Gastroenterol Hepatol 16(2):75–81 PMC8132677 34035705

104. Lorincz M, Kleszky M, Szalóki T Jr et al (2010) Refrakter pyoderma gangraenosum sikeres visilizumabkezelése colitis ulcerosás betegben [Pyoderma gangrenosum treated successfully with visilizumab in patients with ulcerative colitis]. Orv Hetil 151(4):144-7. Hungarian. 10.1556/OH.2010.28786 10.1556/OH.2010.28786 20071320

105. Sen M Dogra S Rathi M Successful treatment of large refractory pyoderma gangrenosum-like presentation of granulomatosis with polyangiitis by rituximab Int J Rheum Dis 2017 20 12 2200 2202 10.1111/1756-185X.12882 27126548 Sen M, Dogra S, Rathi M et al (2017) Successful treatment of large refractory pyoderma gangrenosum-like presentation of granulomatosis with polyangiitis by rituximab. Int J Rheum Dis 20(12):2200–2202. 10.1111/1756-185X.12882 27126548 10.1111/1756-185X.12882

106. DaCunha M Siscos S Downing M Pyoderma gangrenosum controlled with rituximab JAAD Case Rep 2019 5 7 593 595 10.1016/j.jdcr.2019.04.019 31312710 PMC6610635 DaCunha M, Siscos S, Downing M et al (2019) Pyoderma gangrenosum controlled with rituximab. JAAD Case Rep 5(7):593–595. 10.1016/j.jdcr.2019.04.019 31312710 10.1016/j.jdcr.2019.04.019 PMC6610635

107. Velasco-Tamariz V Carreño-Tarragona G Tous-Romero F Dramatic resolution of disseminated pyoderma gangrenosum associated with monoclonal gammopathy after therapy with bortezomib and dexamethasone Int Wound J 2017 14 6 1382 1384 10.1111/iwj.12746 28371346 PMC7949545 Velasco-Tamariz V, Carreño-Tarragona G, Tous-Romero F et al (2017) Dramatic resolution of disseminated pyoderma gangrenosum associated with monoclonal gammopathy after therapy with bortezomib and dexamethasone. Int Wound J 14(6):1382–1384. 10.1111/iwj.12746 28371346 10.1111/iwj.12746 PMC7949545

108. Bostan E Günaydın SD Karaduman A Excellent response to bortezomib in a patient with widespread ulcerative pyoderma gangrenosum accompanied by pulmonary involvement and IgA monoclonal gammopathy Int Wound J 2019 16 4 1052 1054 10.1111/iwj.13135 31044516 PMC7948885 Bostan E, Günaydın SD, Karaduman A et al (2019) Excellent response to bortezomib in a patient with widespread ulcerative pyoderma gangrenosum accompanied by pulmonary involvement and IgA monoclonal gammopathy. Int Wound J 16(4):1052–1054. 10.1111/iwj.13135 31044516 10.1111/iwj.13135 PMC7948885

109. Nahi H Afram G Brauner H Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti-myeloma treatment Int J Dermatol 2021 60 7 e271 e273 10.1111/ijd.15504 33751551 Nahi H, Afram G, Brauner H et al (2021) Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti-myeloma treatment. Int J Dermatol 60(7):e271–e273. 10.1111/ijd.15504 33751551 10.1111/ijd.15504

110. Cespedes DA Gallitano SM Bhutani D Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma Ann Hematol 2022 101 2 441 442 10.1007/s00277-021-04524-w 33860355 Cespedes DA, Gallitano SM, Bhutani D (2022) Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma. Ann Hematol 101(2):441–442. 10.1007/s00277-021-04524-w 33860355 10.1007/s00277-021-04524-w

111. Köken Avşar A Demirci Yıldırım T Sarı İ Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review Rheumatol Int 2024 44 10 2227 2237 10.1007/s00296-024-05560-1 38488863 Köken Avşar A, Demirci Yıldırım T, Sarı İ (2024) Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review. Rheumatol Int 44(10):2227–2237. 10.1007/s00296-024-05560-1 38488863 10.1007/s00296-024-05560-1

112. Park S St Pierre J Onajin O Successful treatment of severe pyoderma gangrenosum and ulcerative colitis with Upadacitinib ACG Case Rep J 2024 11 10 e01531 10.14309/crj.0000000000001531 39399247 PMC11469854 Park S, St Pierre J, Onajin O et al (2024) Successful treatment of severe pyoderma gangrenosum and ulcerative colitis with Upadacitinib. ACG Case Rep J 11(10):e01531. 10.14309/crj.0000000000001531 39399247 10.14309/crj.0000000000001531 PMC11469854

113. Laird ME Tong LX Lo Sicco KI Novel use of Apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum JAAD Case Rep 2017 3 3 228 229 10.1016/j.jdcr.2017.02.019 28443317 PMC5394202 Laird ME, Tong LX, Lo Sicco KI et al (2017) Novel use of Apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum. JAAD Case Rep 3(3):228–229. 10.1016/j.jdcr.2017.02.019 28443317 10.1016/j.jdcr.2017.02.019 PMC5394202

114. Bordeaux ZA Kwatra SG West CE Treatment of pyoderma gangrenosum with apremilast monotherapy JAAD Case Rep 2022 30 8 10 10.1016/j.jdcr.2022.10.001 36345410 PMC9636013 Bordeaux ZA, Kwatra SG, West CE (2022) Treatment of pyoderma gangrenosum with apremilast monotherapy. JAAD Case Rep 30:8–10. 10.1016/j.jdcr.2022.10.001 36345410 10.1016/j.jdcr.2022.10.001 PMC9636013

115. Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) (GEORGE). https://clinicaltrials.gov/study/NCT06563323 . Accessed 01.10.2024

116. Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG). https://clinicaltrials.gov/study/NCT04901325 . Accessed on 01.10.2024

117. Deucravacitinib in PG https://clinicaltrials.gov/study/NCT05821374 . Accessed 01.10.2024

118. Xavier LF Guimarães NS Santos ALSCD Hyperbaric oxygen therapy as an adjuvant treatment in pyoderma gangrenosum: A scoping review J Eur Acad Dermatol Venereol 2024 38 10 e859 e860 10.1111/jdv.19943 38506565 Xavier LF, Guimarães NS, Santos ALSCD et al (2024) Hyperbaric oxygen therapy as an adjuvant treatment in pyoderma gangrenosum: A scoping review. J Eur Acad Dermatol Venereol 38(10):e859–e860. 10.1111/jdv.19943 38506565 10.1111/jdv.19943

119. Budamakuntla L Suryanarayan S Sarvajnamurthy SS Autologous platelet rich plasma in pyoderma gangrenosum - two case reports Indian J Dermatol 2015 60 2 204 205 10.4103/0019-5154.152539 25814720 PMC4372924 Budamakuntla L, Suryanarayan S, Sarvajnamurthy SS et al (2015) Autologous platelet rich plasma in pyoderma gangrenosum - two case reports. Indian J Dermatol 60(2):204–205. 10.4103/0019-5154.152539 25814720 10.4103/0019-5154.152539 PMC4372924

120. Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum. https://clinicaltrials.gov/study/NCT05984654 . Accessed 01.10.2024

121. Novel Therapeutic Treatment of Pyoderma Gangrenosum. https://clinicaltrials.gov/study/NCT05120726 . Accessed 01.10.2024